WO2005121368A1 - Compositions chimeriques oligomeres a breche - Google Patents

Compositions chimeriques oligomeres a breche Download PDF

Info

Publication number
WO2005121368A1
WO2005121368A1 PCT/US2004/017522 US2004017522W WO2005121368A1 WO 2005121368 A1 WO2005121368 A1 WO 2005121368A1 US 2004017522 W US2004017522 W US 2004017522W WO 2005121368 A1 WO2005121368 A1 WO 2005121368A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
nucleosides
oligomeric compound
rna
modified
Prior art date
Application number
PCT/US2004/017522
Other languages
English (en)
Inventor
Balkrishen Bhat
Eric Swayze
Charles Allerson
Prasad Dande
Thazha P. Prakash
Richard H. Griffey
Original Assignee
Isis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals, Inc. filed Critical Isis Pharmaceuticals, Inc.
Priority to PCT/US2004/017522 priority Critical patent/WO2005121368A1/fr
Priority to CA002569036A priority patent/CA2569036A1/fr
Priority to JP2007515019A priority patent/JP2008501335A/ja
Priority to AU2004320622A priority patent/AU2004320622B2/en
Priority to US11/569,941 priority patent/US20080261904A1/en
Priority to EP04754188A priority patent/EP1766052A4/fr
Priority to AU2005252663A priority patent/AU2005252663B2/en
Priority to US11/569,955 priority patent/US20090048192A1/en
Priority to CA002568735A priority patent/CA2568735A1/fr
Priority to AU2005252662A priority patent/AU2005252662B2/en
Priority to EP05757632A priority patent/EP1765416A4/fr
Priority to PCT/US2005/019217 priority patent/WO2005121370A2/fr
Priority to PCT/US2005/019220 priority patent/WO2005121372A2/fr
Priority to JP2007515521A priority patent/JP2008501693A/ja
Priority to JP2007515522A priority patent/JP2008501694A/ja
Priority to US11/569,929 priority patent/US20070275921A1/en
Priority to EP05756325A priority patent/EP1765415A4/fr
Priority to EP05757763A priority patent/EP1766071A4/fr
Priority to PCT/US2005/019219 priority patent/WO2005121371A2/fr
Priority to US11/569,931 priority patent/US20080119427A1/en
Priority to CA002569419A priority patent/CA2569419A1/fr
Publication of WO2005121368A1 publication Critical patent/WO2005121368A1/fr
Priority to US11/565,858 priority patent/US20070167392A1/en
Priority to US11/565,799 priority patent/US20070179106A1/en
Priority to US11/565,794 priority patent/US20070173474A1/en
Priority to US11/565,773 priority patent/US20070123484A1/en
Priority to US11/565,785 priority patent/US20070185047A1/en
Priority to US11/565,841 priority patent/US20070167391A1/en
Priority to US11/565,804 priority patent/US20070173475A1/en
Priority to US11/565,816 priority patent/US20070179107A1/en
Priority to US11/565,823 priority patent/US20070179108A1/en
Priority to US11/565,839 priority patent/US20070179109A1/en
Priority to US11/565,817 priority patent/US20070167390A1/en
Priority to US11/565,833 priority patent/US20070172948A1/en
Priority to US11/565,770 priority patent/US20070166734A1/en
Priority to US11/565,781 priority patent/US20070185046A1/en
Priority to US14/804,743 priority patent/US20160017328A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Definitions

  • the present invention provides oligomeric compounds having sufficient complementarity to hybridize to a nucleic acid target and methods for their use in modulating gene expression.
  • the oligomeric compounds comprise double stranded constructs having a first strand capable of hybridizing to a nucleic acid target and a second strand having sufficient complementarity to hybridize to the first strand.
  • the oligomeric compounds hybridize a portion of a target RNA, or a related nucleic acid target involved in the transcription or translation of a target RNA, resulting in modulation of the activity of the target RNA.
  • dsRNA double-stranded RNA
  • PCT publication WO 01/48183 discloses methods of inhibiting expression of a target gene in a nematode worm involving feeding to the worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of the target gene following ingestion of the food organism by the nematode, or by introducing a DNA capable of producing the double-stranded RNA structure (Bogaert et al., 2001).
  • the posttranscriptional gene silencing defined in Caenorhahditis elegans resulting from exposure to double-stranded RNA (dsRNA) has since been designated as RNA interference (RNAi).
  • dsRNA double-stranded RNA
  • RNAi The interference observed in this reaction is sequence specific, is promoted by dsRNA but not single-stranded RNA, functions by specific mRNA degradation, and requires a minimum length of dsRNA. Furthermore, preincubation of dsRNA potentiates its activity demonstrating that RNAi can be mediated by sequence-specific processes in soluble reactions (Tuschl et al., Genes Dev., 1999, 73, 3191-3197). In subsequent experiments, Tuschl et al., using the Drosophila in vitro system, demonstrated that 21- and 22-nt RNA fragments are the sequence-specific mediators of RNAi.
  • siRNAs short interfering RNAs
  • RNAi As is the case for co-suppression, they showed that antisense RNAs act independently of the RNAi genes rde-1 and rde-4 but require the mutator/RNAi gene mut-7 and a putative DEAD box RNA helicase, mut-14. According to the authors, their data favor the hypothesis that gene silencing is accomplished by RNA primer extension using the mRNA as template, leading to dsRNA that is subsequently degraded suggesting that single-stranded RNA oligomers are ultimately responsible for the RNAi phenomenon (Tijsterman et al., Science, 2002, 295, 694-697). Several recent publications have described the structural requirements for the dsRNA trigger required for RNAi activity.
  • RNA silencing in C. elegans has demonstrated modification of the internucleotide linkage (phosphorothioate) to not interfere with activity (Parrish et al., Molecular Cell, 2000, 6, 1077-1087.) It was also shown by Parrish et al, that chemical modification like 2'-amino or 5'-iodouridine are well tolerated in the sense strand but not the antisense strand of the dsRNA suggesting differing roles for the 2 strands in RNAi. Base modification such as guanine to inosine (where one hydrogen bond is lost) has been demonstrated to decrease RNAi activity independently of the position of the modification (sense or antisense).
  • RNA-DNA heteroduplexes did not serve as triggers for RNAi.
  • dsRNA containing 2'-2'-F modified nucleosides appeared to be efficient in triggering RNAi response independent of the position (sense or antisense) of the 2'-F modified nucleoside.
  • RNAi phenomenon include: PCT publication WO 00/44895; PCT publication WO 00/49035; PCT publication WO 00/63364; PCT publication WO 01/36641; PCT publication WO 01/36646; PCT publication WO 99/32619; PCT publication WO 00/44914; PCT publication WO 01/29058; and PCT publication WO 01/75164.
  • RNA-induced silencing complex RISC
  • elF2Cl and elf2C2 human GERp950 Argonaute proteins.
  • the activity of 5'-phosphorylated single stranded siRNA was comparable to the double stranded siRNA in the system studied.
  • the RNA interference pathway of antisense modulation of gene expression is an effective means for modulating the levels of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications involving gene silencing.
  • the present invention therefore further provides compositions useful for modulating gene expression pathways, including those relying on an antisense mechanism of action such as RNA interference and dsRNA enzymes as well as non-antisense mechanisms.
  • an antisense mechanism of action such as RNA interference and dsRNA enzymes as well as non-antisense mechanisms.
  • compositions comprising a first oligomeric compound and a second oligomeric compound, each having linked nucleosidic bases. At least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, wherein the first oligomeric compound comprises a plurality of linked nucleosides linked by internucleoside linking groups wherein the nucleosides further comprise three regions.
  • Each of the three regions are differentiated from each of the other two regions in at least one aspect by having differentially modified ribofuranosyl sugar moieties or one region comprises ⁇ -D-ribofuranosyl sugar moieties and the other two regions are differentiated from each other in at least one aspect by having differentially modified ribofuranosyl sugar moieties.
  • the second oligomeric compound comprises a plurality of linked ⁇ -D- ribofuranosyl nucleosides linked by internucleoside linking groups.
  • the first and second oligomeric compounds optionally comprise a phosphate group, a 3'- overhang or a conjugate group.
  • each of the regions of modified ribofuranosyl sugar moieties is uniformly modified.
  • At least one region comprises nucleosides having 3'-endo conformational geometry with all three regions comprising nucleosides having 3 '-endo conformational geometry being preferred.
  • each Ri is, independently, H, C ⁇ -C 12 alkyl, a protecting group or substituted or unsubsttuted C ⁇ -C 12 alkyl, C 2 -C 12 alkenyl, or C 2 -C 12 alkynyl wherein the substituent groups are selected from halogen, hydroxyl, amino, azido, cyano, haloalkyl, alkenyl, alkoxy, thioalkoxy, haloalkoxy or aryl.
  • each Ri is, independently, H, C ⁇ -C 12 alkyl, a protecting group or substituted or unsubstituted C ⁇ -C ⁇ 2 alkyl, C 2 -C 12 alkenyl, or C 2 -C 12 alkynyl wherein the substituent groups are selected from halogen, hydroxyl, amino, azido, cyano, haloal
  • An even more preferred group of 2'-substituent groups -F, -O-CH 2 CH 2 -O-CH 3 , - O-CH 3 , -O-CH 2 -CH CH 2 or -O-CH 2 -CH-CH 2 -NH(Rj) where Rj is H or Ci-Cio alkyl. Even more preferred are -F, -O-CH 3 or -O-CH 2 CH 2 -O-CH 3 with -F or -O-CH 3 being even more preferred.
  • a preferred ribofuranosyl modification for one of the regions of the first oligomeric compound include 4'-thio modified nucleosides.
  • compositions include a first oligomeric compound comprising one region of ⁇ -D-ribofuranosyl sugar moieties and two differentially modified regions of ribofuranosyl sugar moieties.
  • a preferred orientation includes having two external regions of differentially modified ribofuranosyl sugar moieties and one internal region of /3-D-ribofuranosyl sugar moieties.
  • a preferred chimeric orientation is to have the 5'-external region comprising 2'-F modified ribofuranosyl sugar moieties or 4'-thio modified ribofuranosyl moieties, the internal region comprises ⁇ -D- ribofuranosyl sugar moieties and the 3'-external region comprises 2'-OCH modified ribofuranosyl sugar moieties, 4'-thio modified ribofuranosyl moieties, modified ribofuranosyl moieties each having a 4'-CH 2 -O-2'-bridge or ribofuranosyl moieties each having a 4'-(CH 2 ) 2 -O-2'-bridge.
  • compositions include a first oligomeric compound comprising the three differentially modified regions of ribofuranosyl sugar moieties wherein each region comprises uniformly modified ribofuranosyl moieties selected from 2'-F modified ribofuranosyl sugar moieties, 2'-OCH modified ribofuranosyl sugar moieties, 4'-thio modified ribofuranosyl moieties, modified ribofuranosyl moieties each having a 4'-CH 2 -O-2'-bridge or ribofuranosyl moieties each having a 4'-(CH 2 ) 2 -O-2'- bridge.
  • a preferred composition includes having the three regions comprise two external regions and one internal region wherein the 5'-external region comprises 4'-thio modified ribofuranosyl moieties, the internal region comprises 2'-F modified ribofuranosyl sugar moieties and the 3'-external region comprises 2'-OCH 3 modified ribofuranosyl sugar moieties, modified ribofuranosyl moieties each having a 4'-CH 2 -O-2'-bridge or ribofuranosyl moieties each having a 4'-(CH 2 ) nn -O-2'-bridge.
  • compositions include a first oligomeric compound comprising two external regions and one internal region wherein the external regions each have from 1 to 6 nucleosides and the internal region has from 6 to 14 nucleosides.
  • a preferred range includes external regions each having from 2 to 5 nucleosides and internal region having from 8 to 13 nucleosides.
  • a more preferred range includes external regions each having from 2 to 5 nucleosides and internal region having from 8 to 13 nucleosides.
  • Another preferred range includes external regions each having from 2 to 5 nucleosides and internal region having from 8 to 13 nucleosides.
  • Especially preferred chimeric gapmers include 20mers having 2-5 nucleosides in each external region and 10-16 nucleosides in the internal region (2-5/10-14/2-5) and 19mers having 1-3 nucleosides in each external region and 13-17 nucleosides in the internal region (1- 3/13-17/1-3).
  • the compositions include at least one 5'-phosphate group.
  • the compositions include a terminal 3'-OH group.
  • the compositions include at least one conjugate group.
  • the nucleosides of each of the first and the second oligomeric compounds are linked by phosphodiester internucleoside linking groups.
  • nucleosides of each of the first and the second oligomeric compounds are linked by phosphorothioate internucleoside linking groups.
  • nucleosides of one the first and the second oligomeric compound are linked by phosphorothioate internucleoside linking groups and the nucleosides of the other of the first and the second oligomeric compound are linked by phosphodiester internucleoside linking groups.
  • nucleosides of the first oligomeric compound are linked by phosphorothioate internucleoside linking groups and the nucleosides of the second oligomeric compound are linked by phosphodiester internucleoside linking groups.
  • nucleosides of the first and the second oligomeric compound are independently linked by phosphorothioate or phosphodiester internucleoside linking groups. In another embodiment at least one of the first and the second oligomeric compounds are independently linked by alternating phosphorothioate and phosphodiester internucleoside linking groups. In one embodiment at least one of the first and the second oligomeric compounds further comprises at least one terminal cap mqiety attached at the 3 '-end, the 5'-end or both the 3'-end and the 5'-end. One preferred terminal cap moiety is an inverted deoxy abasic moiety.
  • compositions include a second oligomeric compound comprising a terminal cap moiety at one or both of the 3'-terminal and the 5'- terminal ends with an inverted deoxy abasic moiety being a preferred terminal cap moiety.
  • the first and the second oligomeric compounds are a complementary pair of siRNA oligonucleotides.
  • each of the first and second oligomeric compounds has from about 8 to about 80 nucleobases with a more preferred range being from about 10 to about 50 nucleobases. Even more preferred ranges include from about 12 to about 30 nucleobases, from about 12 to about 24 nucleobases and from about 19 to about 23 nucleobases.
  • the first oligomeric compound is an antisense oligonucleotide and in another embodiment the second oligomeric compound is a sense oligonucleotide.
  • the compositions include at least one protein wherein the protein comprises at least a portion of an RNA-induced silencing complex (RISC).
  • RISC RNA-induced silencing complex
  • the invention includes methods of inhibiting gene expression comprising contacting one or more cells, a tissue or an animal with a composition of the invention.
  • methods include inliibiting gene expression comprising contacting one or more cells, a tissue or an animal with the first or second oligomeric compound of claim 1.
  • compositions of oligomeric compounds wherein at least a portion of the composition is double stranded and a further portion of the composition is complementary to and hybridizes with a nucleic acid target.
  • the compositions can comprise a single stand with regions of self complementarity thereby forming a loop structure.
  • More preferred compositions include double standed compositions comprising a first and second oligomeric compound where the first oligomeric compound hybridizes to the second oligomeric compound and further has a complementary region that hybridizes to a target nucleic acid. In this capacity the first oligomeric compound is the antisense strand and the second oligomeric compound is the sense strand of the composition.
  • the region of the first oligomeric compound that is complementary to a nucleic acid target comprises nucleosides having 3'-endo sugar conformational geometry.
  • the complementary region preferably comprises a chimeric gapped oligomeric compound wherein an internal region is flanked by two other regions and wherein all the nucleosides have 3'-endo conformational geometry.
  • the three regions are at least differentiated by having different ribofuranosyl subunits that are identical for each individual region.
  • the three regions can have any combination of native or modified internucleoside linkages and native or modified heterocyclic base moieties.
  • the oligomeric compounds can be further modified with modifications such as 5'- phosphate groups and conjugate groups as described herein and as known in the art.
  • the first oligomeric compound comprises a continuous sequence of linked nucleosides that are divided into three distinct regions with each region having at least different ribofuranosyl sugar moieties relative to the other two regions.
  • one of the three regions is a continuous sequence of linked /3-D-ribonucleosides nucleosides and the remaining regions are differentiated by having their ribofuranosyl sugar moieties.
  • Regions not comprised of unmodified RNA (linked -D-ribonucleosides nucleosides) preferably comprise nucleosides having at least uniformly modified ribofuranosyl sugar units which are essentially identical for each region but differ between regions.
  • modified ribofuranosyl sugar moieties include 4'-thioribonucleosides, 2'-substituted ribonucleosides and nucleosides having a 4'-CH 2 -O-2'-bridge or a 4'- (CH 2 ) 2 -O-2' -bridge. More preferred modifications impart 3'-endo sugar conformational geometry to the modified nucleosides.
  • the first oligomeric compound comprises 3 regions, one internal region flanked by two external regions. In one aspect the external regions each have from 1 to about 6 nucleosides with the internal region having from about 6 to about 14 nucleosides.
  • the external regions each have from about 2 to about 5 nucleosides with the internal region having from about 8 to about 13 nucleosides. In a further aspect the external regions each have from about 2 to about 3 nucleosides with the internal region having from about 10 to about 13 nucleosides.
  • Compositions of the present invention will be useful for the modulation of gene expression.
  • a targeted cell, group of cells, a tissue or an animal is contacted with a composition of the invention to effect reduction of message that can directly inhibit gene expression.
  • the reduction of message indirectly upregulates a non-targeted gene through a pathway that relates the targeted gene to a non-targeted gene.
  • compositions of the invention modulate gene expression by hybridizing to a nucleic acid target resulting in loss of its normal function.
  • target nucleic acid or “nucleic acid target” is used for convenience to encompass any nucleic acid capable of being targeted including without limitation DNA, RNA (including pre-mRNA and mRNA or portions thereof) tanscribed from such DNA, and also cDNA derived from such RNA.
  • the target nucleic acid is a messenger RNA.
  • the degradation of the targeted messenger RNA is facilitated by a RISC complex that is formed with oligomeric compounds of the invention.
  • the degradation of the targeted messenger RNA is facilitated by a nuclease such as RNaseH.
  • antisense inhibition The hybridization of an oligomeric compound of this invention with its target nucleic acid is generally referred to as "antisense”. Consequently, the preferred mechanism in the practice of some preferred embodiments of the invention is referred to herein as “antisense inhibition.”
  • antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide stands or segments such that at least one stand or segment is cleaved, degraded, or otherwise rendered inoperable.
  • target specific nucleic acid molecules and their functions for such antisense inhibition The functions of DNA to be interfered with can include replication and tanscription.
  • Replication and tanscription can be from an endogenous cellular template, a vector, a plasmid construct or otherwise.
  • the functions of RNA to be interfered with can include functions such as tianslocation of the RNA to a site of protein tanslaton, tanslocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, tanslaton of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA.
  • modulation and modulation of expression mean either an increase (stimulation) or a decrease (inhibition) in the amount or levels of a nucleic acid molecule encoding the gene, e.g., DNA or RNA. Inhibition is often the preferred form of modulation of expression and mRNA is often a preferred target nucleic acid.
  • the compositions and methods of the present invention are also useful in the study, characterization, validation and modulation of small non-coding RNAs.
  • microRNAs miRNA
  • small nuclear RNAs snRNA
  • small nucleolar RNAs snoRNA
  • small temporal RNAs stRNA
  • tiny non-coding RNAs tncRNA or their precursors or processed tanscripts or their associaton with other cellular components.
  • Small non-coding RNAs have been shown to functon in various developmental and regulatory pathways in a wide range of organisms, including plants, nematodes and mammals.
  • MicroRNAs are small non-coding RNAs that are processed from larger precursors by enzymatc cleavage and inhibit tanslation of mRNAs.
  • compositions of the present invention find utility in the contol and manipulation of cellular functions or processes such as regulaton of splicing, chromosome packaging or methylaton, contol of developmental timing events, increase or decrease of target RNA expression levels depending on the timing of delivery into the specific biological pathway and tanslational or tanscriptional contol.
  • compositions of the present invention can be modified in order to optimize their effects in certain cellular compartments, such as the cytoplasm, nucleus, nucleolus or mitochondria.
  • compositions of the present invention can further be used to identify components of regulatory pathways of RNA processing or metabolism as well as in screening assays or devices.
  • oligomeric compound refers to a polymeric structure capable of hybridizing a region of a nucleic acid molecule. This term includes oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics and chimeric combinations of these. Oligomeric compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and may also include branching. Oligomeric compounds can be included double standed constructs such as for example two stands hybridized to form double standed compounds.
  • the double standed oligomeric compounds can be linked or separate and can have blunt ends, overhangs on the ends or can have a combination including a blunt end and an end with an overhang. Further modifications can include conjugate groups attached to one of the termini, selected nucleobase positions, sugar positions or to one of the internucleoside linkages.
  • an oligomeric compound comprises a backbone of momeric subunits joined linking groups where each linked momeric subunit is directly or indirectly attached to a heterocyclic base moiety.
  • Oligomeric compounds may also include monomeric subunits that are not linked to a heterocyclic base moiety thereby providing abasic sites.
  • nucleoside comprises a sugar moiety attached to a heterocyclic base moiety.
  • heterocyclic base The two most common classes of such heterocyclic bases are purines and pyrimidines.
  • Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside.
  • the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar giving the more common 3', 5-internucleoside linkage or the not so common 2', 5'-internucleoside linkage.
  • the phosphate groups covalently link the sugar moieties of adjacent nucleosides. The respective ends can be joined to form a circular structure by hybridization or by format on of a covalent bond, however, open linear structures are generally preferred.
  • oligonucleotde refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside linkages.
  • oligonucleotide analog refers to oligonucleotides that have one or more non-naturally occurring portions which function in a similar manner to oligonulceotides. Such oligonucleotide analogs are often preferred over the naturally occurring forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a nucleic acid target and enhanced nuclease stability.
  • the term “oligonucleotde” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). This term includes oligonucleotides composed of naturally-occurring nucleobases,
  • oligonucleoside refers to a sequence of nucleosides that are joined by internucleoside linkages that do not have phosphorus atoms. Internucleoside linkages of this type include short chain alkyl, cycloalkyl, mixed heteroatom alkyl, mixed heteroatom cycloalkyl, one or more short chain heteroatomic and one or more short chain heterocyclic.
  • internucleoside linkages include but are not limited to siloxane, sulfide, sulfoxide, sulfone, acetyl, formacetyl, thioformacetyl, methylene formacetyl, thioformacetyl, alkeneyl, sulfamate; methyleneimino, methylenehydrazino, sulfonate, sulfonamide, amide and others having mixed N, O, S and CH 2 component parts.
  • oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.
  • oligomeric compounds such as antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid.
  • these oligomeric compounds may be intoduced in the form of single-standed, double-standed, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops.
  • the oligomeric compounds of the invent on may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid.
  • RNAse H a cellular endonuclease which cleaves the RNA stand of an RNA:DNA duplex or the RNA region of a duplex that has an RNA:DNA region and may have other chemistries to enhance desired properties. It is known in the art that single-standed antsense oligomeric compounds which are "DNA-like" elicit RNAse H.
  • Acttvation of RNase H results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression.
  • Similar roles have been postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.
  • the preferred form of antisense oligomeric compound is a single-standed antisense oligonucleotide, in many species the intoducton of double-standed constructs, such as double-standed RNA (dsRNA) duplexes, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products.
  • dsRNA double-standed RNA
  • the oligomeric compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides/monomeric subunits).
  • the invention embodies oligomeric compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length.
  • the oligomeric compounds of the invention are 10 to 50 nucleobases in length.
  • this embodies oligomeric compounds of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases in length.
  • the oligomeric compounds of the invention are 12 to 30 nucleobases in length.
  • this embodies oligomeric compounds of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length.
  • the oligomeric compounds of the invention are 12 to 24 nucleobases in length.
  • the oligomeric compounds of the invention are 19 to 23 nucleobases in length.
  • One particularly preferred length for oligomeric compounds is from about 12 to about 30 nucleobases.
  • Another particularly preferred length is from about 12 to about 24 nucleobases.
  • a further particularly preferred length is from about 19 to about 23 nucleobases.
  • Chimeric oligomeric compounds It is not necessary for all positions in a oligomeric compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligomeric compound or even at a single monomeric subunit such as a nucleoside within a oligomeric compound.
  • the present invention also includes oligomeric compounds which are chimeric oligomeric compounds. "Chimeric" oligomeric compounds or “chimeras,” in the context of this invention, are oligomeric compounds containing two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a nucleic acid based oligomer.
  • Chimeric oligomeric compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid.
  • An additional region of the oligomeric compound may serve as a substate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
  • RNase H is a cellular endonuclease which cleaves the RNA stand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of inhibition of gene expression.
  • Chimeric oligomeric compounds of the invention may be formed as composite structures of two or more oligonucleotdes, oligonucleotide analogs, oligonucleosides and/or oligonucleotide mimetics as described above.
  • Routinely used chimeric compounds include but are not limited to hybrid, hemimers, gapmers, inverted gapmers and blockmers wherein the various point modificatons and or regions are selected from native or modified DNA and RNA type units and or mimetic type subunits such as for example LNA, ENATM, PNA, mo holinos, and others.
  • Oligomer Mimetics Another preferred group of oligomeric compounds amenable to the present invention includes oligonucleotide mimetics.
  • mimetic as it is applied to oligonucleotides is intended to include oligomeric compounds wherein the furanose ring or the furanose ring and the internucleotide linkage are replaced with novel groups, replacement of only the furanose ring is also referred to in the art as being a sugar surrogate.
  • the heterocyclic base moiety or a modified heterocyclic base moiety is maintained for hybridization with an appropriate target nucleic acid.
  • PNA peptide nucleic acid
  • Representative United States patents that teach the preparatton of PNA oligomeric compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference.
  • PNA's can be obtained commercially from Applied Biosystems (Foster City, CA, USA). Numerous modifications have been made to the basic PNA backbone since it was intoduced in 1991 by Nielsen and coworkers (Nielsen et al, Science, 1991, 254, 1497- 1500).
  • T 4 is hydrogen, an amino protecting group, -C(O)R 5 , substituted or unsubstituted Ci- o alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, substituted or unsubstituted C 2 - Cio alkynyl, alkylsulfonyl, arylsulfonyl, a chemical functional group, a reporter group, a conjugate group, a D or L ⁇ -amino acid linked via the -carboxyl group or optionally through the ⁇ -carboxyl group when the amino acid is aspartic acid or glutamic acid or a peptide derived from D, L or mixed D and L amino acids linked through a carboxyl group, wherein the substituent groups are selected from hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nito, thiol,
  • oligonucleotide mimetic is based on linked morpholino units (morpholino nucleic acid) having heterocyclic bases attached to the morpholino ring.
  • linked morpholino units morpholino nucleic acid
  • a number of linking groups have been reported that link the morpholino monomeric units in a morpholino nucleic acid.
  • a preferred class of linking groups have been selected to give a non-ionic oligomeric compound. The non-ionic morpholino-based oligomeric compounds are less likely to have undesired interactions with cellular proteins.
  • Morpholino-based oligomeric compounds are non-ionic mimics of oligonucleotides which are less likely to form undesired interactions with cellular proteins (Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503- 4510). Morpholino-based oligomeric compounds have been studied in ebrafish embryos (see: Genesis, volume 30, issue 3, 2001 and Heasman, J., Dev. Bio , 2002, 243, 209- 214). Further studies of Morpholino-based oligomeric compounds have also been reported (see: Nasevicius et al, Nat. Genet., 2000, 26, 216-220; and Lacerra et al, Proc.
  • Morpholino-based oligomeric compounds are disclosed in United States Patent 5,034,506, issued July 23, 1991.
  • the morpholino class of oligomeric compounds have been prepared having a variety of different linking groups joining the monomeric subunits.
  • Morpholino nucleic acids have been prepared having a variety of different linking groups (L 2 ) joining the monomeric subunits.
  • the basic formula is shown below:
  • Ti is hydrogen, hydroxyl, a protected hydroxyl, a linked nucleoside or a linked oligomeric compound
  • T 5 is hydrogen or a phosphate, phosphate derivative, a linked nucleoside or a linked oligomeric compound
  • L 2 is a linking group which can be varied from chiral to achiral from charged to neutal
  • a further class of oligonucleotide mimetic is referred to as cyclohexenyl nucleic acids (CeNA).
  • CeNA cyclohexenyl nucleic acids
  • CeNA DMT protected phosphoramidite monomers have been prepared and used for oligomeric compound synthesis following classical phosphoramidite chemistry. Fully modified CeNA oligomeric compounds and oligonucleotides having specific positions modified with CeNA have been prepared and studied (see Wang et al, J. Am. Chem. Soc, 2000, 122, 8595-8602).
  • CeNA oligoadenylates formed complexes with RNA and DNA complements with similar stability to the native complexes.
  • the study of inco ⁇ orating CeNA structures into natural nucleic acid structures was shown by NMR and circular dichroism to proceed with easy conformatonal adaptation. Furthermore the inco ⁇ oration of CeNA into a sequence targeting RNA was stable to serum and able to activate E. Coli RNase resulting in cleavage of the target RNA stand.
  • the general formula of CeNA is shown below:
  • each Bx is a heterocyclic base moiety
  • L 3 is an inter cyclohexenyl linkage such as for example a phosphodiester or a phosphorothioate linkage
  • Ti is hydrogen, hydroxyl, a protected hydroxyl, a linked nucleoside or a linked oligomeric compound
  • T 2 is hydrogen or a phosphate, phosphate derivative, a linked nucleoside or a linked oligomeric compound.
  • Another class of oligonucleotide mimetic can be prepared from one or more anhydrohexitol nucleosides (see, Wouters and Herdewijn, Bioorg. Med. Chem. Lett., 1999, 9, 1563-1566) and would have the general formula:
  • each Bx is a heterocyclic base moiety
  • L is an inter anhydrohexitol linkage such as for example a phosphodiester or a phosphorothioate linkage
  • Ti is hydrogen, hydroxyl, a protected hydroxyl, a linked nucleoside or a linked oligomeric compound
  • T 2 is hydrogen or a phosphate, phosphate derivative, a linked nucleoside or a linked oligomeric compound.
  • a further preferred modification includes bicyclic sugar moieties such as "Locked Nucleic Acids” (LNAs) in which the 2'-hydroxyl group of the ribosyl sugar ring is linked to the 4' carbon atom of the sugar ring thereby forming a 2'-C,4'-C- oxymethylene linkage to form the bicyclic sugar moiety (reviewed in Elayadi et al, Curr. Opinion Invens. Drugs, 2001, 2, 558-561; Braasch et al, Chem. Biol, 2001, 8 1-7; and Orum et al, Curr. Opinion Mol Then, 2001, 3, 239-243; see also U.S.
  • LNAs Locked Nucleic Acids
  • LNA locked nucleic acid used here for 2'-O,4'-methylene-bridged nucleic acid
  • n 2
  • ENATM 2'-O,4'-ethylene-bridged nucleic acid
  • LNA's are commercially available from ProLigo (Paris, France and Boulder, CO, USA). The basic structure of LNA showing the bicyclic ring system is shown below:
  • each Ti and T 2 is, independently, hydrogen, a hydroxyl protecting group, a linked nucleoside or a linked oligomeric compound, and each Zi is an internucleoside linking group such as for example phosphodiester or phosphorothioate.
  • An isomer of LNA that has also been studied is V-L-LNA which has been shown to have superior stability against a 3'-exonuclease (Frieden et al, Nucleic Acids Research, 2003, 21, 6365-6372). The V-L-LNA's were inco ⁇ orated into antisense gapmers and chimeras that showed potent antisense activity.
  • the structure of V-L-LNA is shown below:
  • LNA has been shown to form exceedingly stable LNA:LNA duplexes (Koshkin et al., J. Am. Chem. Soc, 1998, 120, 13252-13253).
  • LNALNA hybridization was shown to be the most thennally stable nucleic acid type duplex system, and the RNA- mimicking character of LNA was established at the duplex level.
  • LNA-mediated hybridization has been stessed by the formation of exceedingly stable LNALNA duplexes.
  • the RNA-mimicking of LNA was reflected with regard to the N-type conformational restrict on of the monomers and to the secondary structure of the LNA:RNA duplex.
  • LNAs also form duplexes with complementary DNA, RNA or LNA with high thermal affinites.
  • Circular dichroism (CD) specta show that duplexes involving fully modified LNA (esp. LNA:RNA) structurally resemble an A-form RNA:RNA duplex.
  • Nuclear magnetic resonance (NMR) examination of an LNA:DNA duplex confirmed the 3'-endo conformation of an LNA monomer.
  • antisense applications PCR applications, stand-displacement oligomers, substates for nucleic acid polymerases and generally as nucleotde based drugs.
  • Potent and nontoxic antisense oligonucleotides containing LNAs have been described (Wahlestedt et al., Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 5633-5638.) The authors have demonstated that LNAs confer several desired properties to antisense agents. LNA DNA copolymers were not degraded readily in blood serum and cell extacts.
  • LNA/DNA copolymers exhibited potent antisense activity in assay systems as disparate as G-protein-coupled receptor signaling in living rat brain and detection of reporter genes in Escherichia coli. Lipofectin-mediated efficient delivery of LNA into living human breast cancer cells has also been accomplished. Further successful in vivo studies involving LNA's have shown knock-down of the rat delta opioid receptor without toxicity (Wahlestedt et al, Proc. Natl. Acad. Sci., 2000, 97, 5633-5638) and in another study showed a blockage of the tanslation of the large subunit of RNA polymerase II (Flutter et al, Nucleic Acids Res., 2003, 31, 953-962).
  • LNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their oligomerization, and nucleic acid recognition properties have been described (Koshkin et al., Tetahedron, 1998, 54, 3607- 3630). LNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226. The first analogs of LNA, phosphorothioate-LNA and 2'-thio-LNAs, have also been prepared (Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222).
  • oligonucleotide mimetic amenable to the present invention is threose nucleic acid.
  • This oligonucleotide mimetic is based on threose nucleosides instead of ribose nucleosides and has the general structure shown below:
  • TNA (3',2')-V-L-threose nucleic acid
  • Oligomeric compounds containing bicyclic nucleoside analogs have shown thermal stabilities approaching that of DNA duplexes.
  • Another class of oligonucleotide mimetic is referred to as phosphonomonoester nucleic acids which inco ⁇ orate a phosphorus group in the backbone.
  • This class of olignucleotide mimetic is reported to have useful physical and biological and pharmacological properties in the areas of inhibiting gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming oligonucleotides), as probes for the detectton of nucleic acids and as auxiliaries for use in molecular biology.
  • the general formula for definitions of Markush variables see: United States Patents 5,874,553 and 6,127,346 herein inco ⁇ orated by reference in their entirety) is shown below.
  • nucleoside is a base-sugar combination.
  • the base portion of the nucleoside is normally a heterocyclic base.
  • the two most common classes of such heterocyclic bases are the purines and the pyrimidines.
  • Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside.
  • the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar.
  • the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound.
  • the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally preferred.
  • linear compounds may have internal nucleobase complementarity and may therefore fold in a manner as to produce a fully or partially double-standed compound.
  • the phosphate groups are commonly refened to as forming the internucleoside linkage or in conjunction with the sugar ring the backbone of the oligonucleotide.
  • the normal internucleoside linkage that makes up the backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.
  • Modified Internucleoside Linkages Specific examples of preferred antisense oligomeric compounds useful in this invention include oligonucleotides containing modified e.g. non-naturally occurring internucleoside linkages. As defined in this specification, oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom and internucleoside linkages that do not have a phosphorus atom. For the pu ⁇ oses of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. , In the C.
  • prefened oligomeric compounds of the invention can also have one or more modified internucleoside linkages.
  • a prefened phosphorus containing modified internucleoside linkage is the phosphorothioate internucleoside linkage.
  • Prefened modified oligonucleotde backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphoro- dithioates, phosphotriesters, aminoalkylphosphotiesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3 '-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotiesters, phosphonoacetate and thiophosphonoacetate (see Sheehan et al, Nucleic Acids Research, 2003, 31(14), 4109-4118 and Dellinger et al, J.
  • oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof).
  • N3'-P5'-phosphoramidates have been reported to exhibit both a high affinity towards a complementary RNA stand and nuclease resistance (Gryaznov et al, J. Am. Chem. Soc, 1994, 116, 3143-3144). N3'-P5'-phosphoramidates have been studied with some success in vivo to specifically down regulate the expression of the c-myc gene (Skorski et al, Proc. Natl. Acad. Sci, 1997, 94, 3966-3971; and Faira et al, Nat. Biotechnol, 2001, 19, 40-44).
  • MMI type internucleoside linkages are disclosed in the above referenced U.S. patent 5,489,677.
  • Prefened amide internucleoside linkages are disclosed in the above referenced U.S. patent 5,602,240.
  • Prefened modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
  • mo ⁇ holino linkages formed in part from the sugar portion of a nucleoside
  • siloxane backbones sulfide, sulfoxide and sulfone backbones
  • formacetyl and thioformacetyl backbones methylene formacetyl and thioformacetyl backbones
  • riboacetyl backbones alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH 2 component parts.
  • oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein inco ⁇ orated by reference.
  • Modified sugars Oligomeric compounds of the invention may also contain one or more substituted or other wise modified sugar moietes. Ribosyl and related sugar moieties are routinely modified at any reactive position not involved in linking. Thus a prefened position for a sugar substituent group is the 2'-position not usually used in the native 3' to 5'- internucleoside linkage. Other prefened positions are the 3' and the 5'-termini. 3'-sugar positions are open to modification when the linkage between two adjacent sugar units is a 2', 5'-linkage. Prefened sugar substituent groups include: OH; F; O-, S-, or N-alkyl; O-
  • alkyl, alkenyl and alkynyl may be substituted or unsubstituted Ci to C 10 alkyl or C 2 to C ⁇ 0 alkenyl and alkynyl.
  • Particularly prefened are O[(CH 2 ) n O] m CH 3 , O(CH 2 ) n OCH 3 , O(CH 2 ) n NH 2 , O(CH 2 ) n CH 3 , O(CH 2 ) n ONH 2 , and O(CH 2 ) n ON[(CH 2 )nCH 3 ] 2 , where n and m are from 1 to about 10.
  • oligonucleotides comprise a sugar substituent group selected from: Ci to Cio lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, CI, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties.
  • a sugar substituent group selected from: Ci to Cio lower alkyl, substituted lower
  • a prefened modification includes 2'-methoxyethoxy (2'-O-CH 2 CH 2 OCH 3 , also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al, Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group.
  • 2'-Sugar substituent groups may be in the arabino (up) position or ribo (down) position.
  • a prefened 2'-arabino modification is 2'-F (see: Loc et al, Biochemistry, 2002, 41, 3457-3467).
  • Similar modifications may also be made at other positions on the oligomeric compoiund, particularly the 3' position of the sugar on the 3' terminal nucleoside or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.
  • Oligomeric compounds may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
  • R b is O, S orNH;
  • R p and Rq are each independently hydrogen or C1-C1 0 alkyl;
  • R r is -R x -Ry;
  • each R s , R t , R u and R v is, independently, hydrogen, C(O)R w , substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C ⁇ 0 alkenyl, substituted or unsubstituted C 2 -C ⁇ o alkynyl, alkylsulfonyl, arylsulfonyl, a chemical functional group or a conjugate group, wherein the substituent groups are selected from hydroxyf, amino, alkoxy, carboxy, benzyl, phenyl, nito, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl; or optionally, R u and R v , together
  • Representative substituents groups of Formula I are disclosed in United States Patent Application Serial No. 09/130,973, filed August 7, 1998, entitled “Capped 2'-Oxyethoxy Oligonucleotides,” hereby inco ⁇ orated by reference in its entirety.
  • Representative cyclic substituent groups of Formula II are disclosed in United States Patent Application Serial No. 09/123,108, filed July 27, 1998, entitled “RNA Targeted 2'-Oligomeric compounds that are Conformationally Preorganized,” hereby inco ⁇ orated by reference in its entirety.
  • Particularly prefened sugar substituent groups include O[(CH 2 ) n O] m CH 3 , O(CH 2 ) n OCH 3 , O(CH 2 ) n NH 2 , O(CH 2 ) n CH 3 , 0(CH 2 ) n ONH 2 , and O(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2) where n and m are from 1 to about 10.
  • Representative guanidino substituent groups that are shown in formula III and IV are disclosed in co-owned United States Patent Application 09/349,040, entitled “Functionalized Oligomers", filed July 7, 1999, hereby inco ⁇ orated by reference in its entirety.
  • Representative acetamido substituent groups are disclosed in United States Patent
  • Oligomeric compounds may also include nucleobase (often refened to in the art simply as “base” or “heterocyclic base moiety") modifications or substitutions.
  • nucleobase often refened to in the art simply as “base” or “heterocyclic base moiety” modifications or substitutions.
  • “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
  • Modified nucleobases also refened herein as heterocyclic base moieties include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2- thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (- C ⁇ C-CH 3 ) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8- thiol, 8-thioalkyl, 8-hydroxyl and
  • Heterocyclic base moieties may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7- deazaguanosine, 2-aminopyridine and 2-pyridone.
  • Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.I., ed.
  • nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5- substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
  • Oligomeric compounds of the present invention can also include polycyclic heterocyclic compounds in place of one or more heterocyclic base moieties. A number of ticyclic heterocyclic comounds have been previously reported.
  • dC5 me 5-methyl cytosine
  • the gain in helical stability does not compromise the specificity of the oligonucleotides.
  • the T m data indicate an even greater discrimination between the perfect match and mismatched sequences compared to dC5 me .
  • Conjugates Oligomeric compounds used in the compositions of the present invention can also be modified to have one or more moieties or conjugates for enhancing the activity, cellular distribution or cellular uptake of the resulting oligomeric compounds.
  • such modified oligomeric compounds are prepared by covalently attaching conjugate groups to functional groups such as hydroxyl or amino groups.
  • Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetc properties of oligomers.
  • Typical conjugates groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes such as including Cy3 and Alexa.
  • Groups that enhance the pharmacodynamic properties include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or stengthen sequence-specific hybridization with RNA.
  • Groups that enhance the pharmacokinetic properties include groups that improve oligomer uptake, distributon, metabolism or excreton.
  • Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-titylthiol (Manoharan et al., Ann. NY. Acad.
  • the oligomeric compounds of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, ca ⁇ rofen, dansylsarcosine, 2,3,5-triiodo- benzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.
  • active drug substances for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)
  • Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is inco ⁇ orated herein by reference in its entirety.
  • Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582;
  • Oligomeric compounds used in the compositions of the present invention can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of oligomeric compounds to enhance properties such as for example nuclease stability. Included in stabilizing groups are cap structures. By “cap structure or terminal cap moiety” is meant chemical modificationsons, which have been inco ⁇ orated at either terminus of oligonucleotides (see for example Wincott et al., WO 97/26270, inco ⁇ orated by reference herein). These terminal modifications protect the oligomeric compounds having terminal nucleic acid molecules from exonuclease degradation, and can help in delivery and/or localization within a cell.
  • the cap can be present at the 5'- terminus (5'-cap) or at the 3'-terminus (3'-cap) or can be present on both termini.
  • the 5'-cap includes inverted abasic residue (moiety), 4',5'-methylene nucleotide; l-(beta-D-erythrofuranosyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl riucleotide, 3
  • Particularly prefened 3 '-cap structures of the present invention include, for example 4',5'-methylene nucleotde; l-(beta-D-erythrofuranosyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; l,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3',4'-
  • oligomeric compounds include nucleosides synthetcally modified to induce a 3'-endo sugar conformation.
  • a nucleoside can inco ⁇ orate synthetic modifications of the heterocyclic base, the sugar moiety or both to induce a desired 3'-endo sugar conformation.
  • These modified nucleosides are used to mimic RNA like nucleosides so that particular properties of an oligomeric compound can be enhanced while maintaining the desirable 3'-endo conformational geometry.
  • RNA type duplex A form helix, predominantly 3'-endo
  • RNA interference which is supported in part by the fact that duplexes composed of 2'-deoxy-2'-F-nucleosides appears efficient in triggering RNAi response in the C. elegans system.
  • Properties that are enhanced by using more stable 3'-endo nucleosides include but aren't limited to modulation of pharmacokinetic properties through modification of protein binding, protein off-rate, abso ⁇ tion and clearance; modulation of nuclease stability as well as chemical stability; modulation of the binding affinity and specificity of the oligomer (affinity and specificity for enzymes as well as for complementary sequences); and increasing efficacy of RNA cleavage.
  • the present invention provides oligomeric triggers of RNAi having one or more nucleosides modified in such a way as to favor a C3'-endo type conformation. Conformation Scheme
  • C2'-endo/Southern C3 '-endo/Northern Nucleoside conformation is influenced by various factors including substitution at the 2', 3' or 4'-positions of the pentofuranosyl sugar.
  • Electonegative substituents generally prefer the axial positions, while sterically demanding substituents generally prefer the equatorial positions (Principles of Nucleic Acid Structure, Wolfgang Sanger, 1984, Springer- Verlag.) Modificaton of the 2' position to favor the 3'-endo conformation can be achieved while maintaining the 2'-OH as a recognition element, as illustated in Figure 2, below (Gallo et al., Tetrahedron (2001), 57, 5707-5713.
  • preference for the 3'-endo conformation can be achieved by deletion of the 2'-OH as exemplified by 2'deoxy-2'F-nucleosides (Kawasaki et al., J. Med. Chem. (1993), 36, 831-841), which adopts the 3'-endo conformation positioning the electonegatve fluorine atom in the axial position.
  • oligomeric triggers of RNAi response might be composed of one or more nucleosides modified in such a way that conformation is locked into a C3'-endo type conformation, i.e. Locked Nucleic Acid (LNA, Singh et al, Chem. Commun. (1998), 4, 455-456), and ethylene bridged Nucleic Acids (ENATM, Morita et al, Bioorganic & Medicinal Chemistry Letters (2002), 12, 73-76.)
  • LNA Locked Nucleic Acid
  • ENATM ethylene bridged Nucleic Acids
  • the prefened conformation of modified nucleosides and their oligomers can be estimated by various methods such as molecular dynamics calculations, nuclear magnetic resonance spectoscopy and CD measurements.
  • modifications predicted to induce RNA like conformations, A-form duplex geometry in an oligomeric context, are selected for use in the modified oligonucleotides of the present invention.
  • the synthesis of numerous of the modified nucleosides amenable to the present invention are known in the art (see for example, Chemistry of Nucleosides and Nucleotdes Vol 1-3, ed. Leroy B. Townsend, 1988, Plenum press., and the examples section below.)
  • the present invention is directed to oligomers that are prepared having enhanced properties compared to native RNA against nucleic acid targets.
  • a target is identified and an oligomer is selected having an effective length and sequence that is complementary to a portion of the target sequence.
  • Each nucleoside of the selected sequence is scrutinized for possible enhancing modifications.
  • a prefened modification would be the replacement of one or more RNA nucleosides with nucleosides that have the same 3'-endo conformational geometry.
  • Such modifications can enhance chemical and nuclease stability relative to native RNA while at the same time being much cheaper and easier to synthesize and/or inco ⁇ orate into an oligonucleotide.
  • the selected sequence can be further divided into regions and the nucleosides of each region evaluated for enhancing modifications that can be the result of a chimeric configuration. Consideration is also given to the 5' and 3 '-termini as there are often advantageous modifications that can be made to one or more of the terminal nucleosides.
  • the oligomeric compounds of the present invention include at least one 5'- modified phosphate group on a single stand or on at least one 5'-positon of a double standed sequence 1 or sequences. Further modifications are also considered such as internucleoside linkages, conjugate groups, substitute sugars or bases, substitution of one or more nucleosides with nucleoside mimetics and any other modification that can enhance the selected sequence for its intended target.
  • the terms used to describe the conformational geometry of homoduplex nucleic acids are "A Form” for RNA and "B Form” for DNA. The respective conformational geometry for RNA and DNA duplexes was determined from X-ray diffraction analysis of nucleic acid fibers (Amott and Hukins, Biochem. Biophys.
  • RNA:RNA duplexes are more stable and have higher melting temperatures (Tm's) than DNA:DNA duplexes (Sanger et al., Principles of Nucleic Acid Structure, 1984, Springer- Verlag; New York, NY.; Lesnik et al., Biochemistry, 1995, 34, 10807-10815; Conte et al., Nucleic Acids Res., 1997, 25, 2627-2634).
  • Tm's melting temperatures
  • RNA biases the sugar toward a C3' endo pucker, i.e., also designated as Northern pucker, which causes the duplex to favor the A-form geometry.
  • a C3' endo pucker i.e., also designated as Northern pucker
  • the 2' hydroxyl groups of RNA can form a network of water mediated hydrogen bonds that help stabilize the RNA duplex (Egli et al., Biochemistry, 1996, 35, 8489-8494).
  • deoxy nucleic acids prefer a C2' endo sugar pucker, i.e., also known as Southern pucker, which is thought to impart a less stable B-form geometry (Sanger, W. (1984) Principles of Nucleic Acid Structure, Springer- Verlag, New York, NY).
  • B-form geometry is inclusive of both C2'-endo pucker and O4'-endo pucker. This is consistent with Berger, et. al, Nucleic Acids Research, 1998, 26, 2473-2480, who pointed out that in considering the furanose conformatons which give rise to B-form duplexes consideration should also be given to a O4'-endo pucker contribution.
  • DNA:RNA hybrid duplexes are usually less stable than pure
  • RNA:RNA duplexes and depending on their sequence may be either more or less stable than DNA:DNA duplexes (Searle et al, Nucleic Acids Res., 1993, 21, 2051-2056).
  • the structure of a hybrid duplex is intermediate between A- and B-form geometries, which may result in poor stacking interactions (Lane et al, Eur. J. Biochem., 1993, 215, 297- 306; Fedoroff et al, J. Mol. Biol, 1993, 233, 509-523; Gonzalez et al, Biochemistry, 1995, 34, 4969-4982; Horton et al, J. Mol. Biol, 1996, 264, 521-533).
  • the stability of the duplex formed between a target RNA and a synthetic sequence is cental to therapies such as but not limited to antisense and RNA interference as these mechanisms require the binding of a synthetic oligomer stand to an RNA target stand.
  • therapies such as but not limited to antisense and RNA interference as these mechanisms require the binding of a synthetic oligomer stand to an RNA target stand.
  • antisense effective inhibition of the mRNA requires that the antisense DNA have a very high binding affinity with the mRNA. Otherwise the desired interaction between the synthetic oligomer stand and target mRNA stand will occur infrequently, resulting in decreased efficacy.
  • One routinely used method of modifying the sugar puckering is the substitution of the sugar at the 2'-position with a substituent group that influences the sugar geometry. The influence on ring conformation is dependant on the nature of the substituent at the 2'-position.
  • the relative duplex stability can be enhanced by replacement of 2'- OH groups with 2'-F groups thereby increasing the C3'-endo population. It is assumed that the highly polar nature of the 2'-F bond and the exteme preference for C3'-endo puckering may stabilize the stacked conformation in an A-form duplex. Data from UV hypochromicity, circular dichroism, and H NMR also indicate that the degree of stacking decreases as the electonegativity of the halo substituent decreases. Furthermore, steric bulk at the 2'-position of the sugar moiety is better accommodated in an A- form duplex than a B-form duplex.
  • a 2'-substituent on the 3'-terminus of a dinucleoside monophosphate is thought to exert a number of effects on the stacking conformation: steric repulsion, furanose puckering preference, electostatic repulsion, hydrophobic attraction, and hydrogen bonding capabilities. These substituent effects are thought to be determined by the molecular size, electonegativity, and hydrophobicity of the substituent. Melting temperatures of complementary stands is also increased with the 2'-substituted adenosine diphosphates. It is not clear whether the 3'-endo preference of the conformation or the presence of the substituent is responsible for the increased binding.
  • Oligomers having the 2'-0-methoxyethyl substituent also have been shown to be antisense inhibitors of gene expression with promising features for in vivo use (Martin, P., Helv. Chim. Acta, 1995, 78, 486-504; Altnann et al, Chimia, 1996, 50, 168-176; Altnann et al, Biochem. Soc. Trans., 1996, 24, 630-637; and Altnann et al, Nucleosides Nucleotides, 1997, 16, 917-926). Relative to DNA, the oligomers having the 2'-MOE modification displayed improved RNA affinity and higher nuclease resistance.
  • Chimeric oligomers having 2'-MOE substituents in the wing nucleosides and an internal region of deoxy-phosphorothioate nucleotides have shown effective reduction in the growth of tumors in animal models at low doses.
  • 2'-MOE substituted oligomers have also shown outstanding promise as antisense agents in several disease states.
  • One such MOE substituted oligomer is presently being investigated in clinical trials for the teatnent of CMV retinitis.
  • the conditions used for the crystallization were 2 mM oligonucleotide, 50 mM Na Hepes pH 6.2-7.5, 10.50 mM MgCl 2 , 15% PEG 400.
  • the resolution was 1.7 A at -170°C.
  • This crystal structure is believed to be the first crystal structure of a fully modified RNA oligonucleotide analogue.
  • the duplex adopts an overall A-form conformation and all modified sugars display CV-endo pucker.
  • the torsion angle around the A'-B' bond, as depicted in Structure II below, of the ethylene glycol linker has a gauche conformation.
  • A' and B' of Structure II below are methylene moieties of the ethyl portion of the MOE and R' is the methoxy portion.
  • the 2'-MOE RNA duplex adopts a general orientation such that the crystallographic 2-fold rotation axis does not coincide with the molecular 2-fold rotation axis.
  • the duplex adopts the expected A-type geometry and all of the 242'-MOE substituents were visible in the electon density maps at full resoluton.
  • the electon density maps as well as the temperature factors of substituent atoms indicate flexibility of the 2'-MOE substituent in some cases.
  • Most of the 2'-MOE substituents display a gauche conformation around the C-C bond of the ethyl linker. However, in two cases, a trans conformation around the C-C bond is observed.
  • the lattice interactions in the crystal include packing of duplexes against each other via their minor grooves. Therefore, for some residues, the conformation of the 2'-O-substituent is affected by contacts to an adjacent duplex.
  • variations in the conformation of the substituents create a range of interactions between substituents, both inter-stand, across the minor groove, and inta-stand.
  • atoms of substituents from two residues are in van der Waals contact across the minor groove.
  • a close contact occurs between atoms of substituents from two adjacent inta-stand residues.
  • the computer simulations were conducted on compounds of SEQ ID NO: 1, above, having 2'-O-modifications located at each of the nucleosides of the oligonucleotide.
  • the simulations were performed with the oligonucleotide in aqueous solution using the AMBER force field method (Cornell et al, J. Am. Chem. Soc, 1995, 117, 5179-5197)(modeling software package from UCSF, San Francisco, CA).
  • the calculations were performed on an Indigo2 SGI machine (Silicon Graphics, Mountain View, CA).
  • 2'-O-modifications that will have a 3 '-endo sugar influence include those having a ring structure that inco ⁇ orates a two atom portion conesponding to the A' and B' atoms of Structure II.
  • the ring structure is attached at the 2' posit on of a sugar moiety of one or more nucleosides that are inco ⁇ orated into an oligonucleotide.
  • the 2'- oxygen of the nucleoside links to a carbon atom conesponding to the A' atom of Structure II.
  • These ring structures can be aliphatic, unsaturated aliphatic, aromatic or heterocyclic.
  • a further atom of the ring bears a further oxygen atom, or a sulfur or nitogen atom.
  • This oxygen, sulfur or nitogen atom is bonded to one or more hydrogen atoms, alkyl moietes, or haloalkyl moieties, or is part of a further chemical moiety such as a ureido, carbamate, amide or amidine moiety.
  • the remainder of the ring structure restricts rotation about the bond joining these two ring atoms.
  • the ability of oligonucleotdes to bind to their complementary target stands is compared by determining the meltng temperature (T m ) of the hybridization complex of the oligonucleotide and its complementary stand.
  • T m meltng temperature
  • the meltng temperature (T m ) a characteristic physical property of double helices, denotes the temperature (in degrees centigrade) at which 50% helical (hybridized) versus coil (unhybridized) forms are present.
  • T m is measured by using the UV spectrum to determine the formation and breakdown (melting) of the hybridization complex.
  • a gauche interaction between the oxygen atoms around the O-C-C-O torsion of the side chain may have a stabilizing effect on the duplex (Freier ibid.).
  • Such gauche interactions have been observed experimentally for a number of years (Wolfe et al, Ace Chem. Res., 1972, 5, 102; Abe et al, J. Am. Chem. Soc, 1976, 98, 468).
  • This gauche effect may result in a configuration of the side chain that is favorable for duplex formation. The exact nature of this stabilizing configuration has not yet been explained.
  • Representative 2'-substituent groups amenable to the present invention that give A-form conformational properties (3 '-endo) to the resultant duplexes include 2'-O-alkyl, 2'-O-substituted alkyl and 2'-fluoro substituent groups.
  • Prefened for the substituent groups are various alkyl and aryl ethers and thioethers, amines and monoalkyl and dialkyl substituted amines.
  • oligomeric compounds of the invention at multiple sites of one or more monomeric subunits (nucleosides are prefened) and or internucleoside linkages to enhance properties such as but not limited to activity in a selected application.
  • Tables I through VII list nucleoside and intemucleotide linkage modifications/replacements that have been shown to give a positive eTm per modification when the modification/replacement was made to a DNA stand that was hybridized to an RNA complement.
  • This modification can increase the Tm of oligonucleotides but can also decrease the Tm depending on positioning and number (motiff dependant).
  • Substitution at Ri can be stabilizing
  • substitution at R 2 is generally greatly destabilizing (unable to form anti conformation)
  • motiffs with stabilizing 5 and 2'- substituent groups are generally additive e.g. increase stability.
  • Substitution of the 04 and 02 positions of 2'-O-methyl uridine was greatly duplex destabilizing as these modifications remove hydrogen binding sites that would be an expected result. 6-Aza T also showed exteme destabilization as this substitution reduces the pK a and shifts the nucleoside toward the enol tautomer resulting in reduced hydrogen bonding.
  • Table VI DNA stand having at least one modified phosphorus containing internucleoside linkage and the effect on the Tm against an RNA complement: eTm/mod + eTm/mod - phosphorothioate 1 phosphoramidate 1 methyl phosphonates 1 (We of the non-bridging oxygen atoms replaced with S, N(H)R or -CH 3 ) phosphoramidate (the 3'-bridging atom replaced with an N(H)R group, stabilization effect enhanced when also have 2'-F)
  • This modification can increase the Tm of oligonucleotides but can also decrease the Tm depending on positioning and number (motiff dependant). Notes: In general carbon chain intemucleotide linkages were destabilizing to duplex fonnation. This destabilization was not as severe when double and tipple bonds were utilized. The use of glycol and flexible ether linkages were also destabilizing.
  • Prefened ring structures of the invention for inclusion as a 2'-O modification include cyclohexyl, cyclopentyl and phenyl rings as well as heterocyclic rings having spacial footprints similar to cyclohexyl, cyclopentyl and phenyl rings.
  • Particularly prefened 2'-O-substituent groups of the invention indued but are not limited to 2'-O- (tans 2-methoxy cyclohexyl, 2'-O-(tans 2-methoxy cyclopentyl, 2'-O-(tans 2-ureido cyclohexyl) and 2'-O-(tans 2-methoxyphenyl).
  • DNA:RNA hybrids are usually less stable than RNA:RNA duplexes and, in some cases, even less stable than DNA:DNA duplexes.
  • Available experimental data attributes the relatively lowered stability of DNA:RNA hybrids largely to its intermediate conformational nature between DNA:DNA (B-family) and RNA:RNA (A-family) duplexes.
  • the overall thermodynamic stability of nucleic acid duplexes may originate from several factors including the conformation of backbone, base-pairing and stacking interactions.
  • the SMe_DNA:RNA hybrid structure possesses an average rise value of 3.2 A which is quite close to that of B-family duplexes.
  • some local base-steps (CG steps) may be observed to have unusually high rise values (as high as 4.5A).
  • CG steps local base-steps
  • the greater destabilization of 2'-S-methyl substituted DNA:RNA hybrids may be partly attributed to poor stacking interactions.
  • alkyl means C 1 -C 1 2, preferably C 1 -G 3 , and more preferably C ⁇ -C 6 , staight or (where possible) branched chain aliphatic hydrocarbyl.
  • heteroalkyl means C ⁇ -Cj 2 , preferably C ⁇ -C 8 , and more preferably C ⁇ -C 6 , staight or (where possible) branched chain aliphatic hydrocarbyl containing at least one, and preferably about 1 to about 3, hetero atoms in the chain, including the terminal portion of the chain. Prefened heteroatoms include N, O and S.
  • cycloalkyl means C 3 -C ⁇ 2 , preferably C 3 -C 8 , and more preferably C -C 6 , aliphatic hydrocarbyl ring.
  • alkenyl means C 2 -C ⁇ 2 , preferably C 2 -C 8 , and more preferably C 2 -C 6 alkenyl, which may be staight or (where possible) branched hydrocarbyl moiety, which contains at least one carbon-carbon double bond.
  • alkynyl means C 2 -C ⁇ 2 , preferably C 2 -C 8 , and more preferably C 2 -C 6 alkynyl, which may be staight or (where possible) branched hydrocarbyl moiety, which contains at least one carbon-carbon triple bond.
  • heterocycloalkyl means a ring moiety containing at least three ring members, at least one of which is carbon, and of which 1, 2 or three ring members are other than carbon.
  • the number of carbon atoms varies from 1 to about 12, preferably 1 to about 6, and the total number of ring members varies from three to about 15, preferably from about 3 to about 8.
  • Prefened ring heteroatoms are N, O and S.
  • Prefened heterocycloalkyl groups include mo ⁇ holino, thiomo ⁇ holino, piperidinyl, piperazinyl, homopiperidinyl, homopiperazinyl, homomo ⁇ holino, homothiomo ⁇ holino, pynolodinyl, tetahydrooxazolyl, tetahydroimidazolyl, tetahydrothiazolyl, tetahydroisoxazolyl, tetahydropynazolyl, furanyl, pyranyl, and tetahydroisothiazolyl.
  • aryl means any hydrocarbon ring structure containing at least one aryl ring.
  • Prefened aryl rings have about 6 to about 20 ring carbons.
  • Especially prefened aryl rings include phenyl, napthyl, anthracenyl, and phenanthrenyl.
  • heteroaryl means a ring moiety containing at least one fully unsaturated ring, the ring consisting of carbon and non-carbon atoms.
  • the ring system contains about 1 to about 4 rings.
  • the number of carbon atoms varies from 1 to about 12, preferably 1 to about 6, and the total number of ring members varies from three to about 15, preferably from about 3 to about 8.
  • Prefened ring heteroatoms are N, O and S.
  • Prefened heteroaryl moieties include pyrazolyl, thiophenyl, pyridyl, imidazolyl, tetazolyl, pyridyl, pyrimidinyl, purinyl, quinazolinyl, quinoxalinyl, benzimidazolyl, benzothiophenyl, etc.
  • a moiety is defined as a compound moiety, such as heteroarylalkyl (heteroaryl and alkyl), aralkyl (aryl and alkyl), etc.
  • each of the sub-moieties is as defined herein.
  • an electon withdrawing group is a group, such as the cyano or isocyanato group that draws electonic charge away from the carbon to which it is attached.
  • Other electon withdrawing groups of note include those whose electonegativities exceed that of carbon, for example halogen, nitro, or phenyl substituted in the ortho- or para-position with one or more cyano, isothiocyanato, nito or halo groups.
  • the terms halogen and halo have their ordinary meanings.
  • Prefened halo (halogen) substituents are CI, Br, and I.
  • the aforementioned optional substituents are, unless otherwise herein defined, suitable substituents depending upon desired properties.
  • halogens include those described in US Patents No.
  • Oligomer Synthesis Oligomerization of modified and unmodified nucleosides is performed according to literature procedures for DNA (Protocols for Oligonucleotides and Analogs, Ed.
  • oligomeric compounds of the invention may be conveniently and routinely made through the well-known technique of solid phase synthesis.
  • Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed.
  • oligonucleotides such as the phosphorothioates and alkyiated derivatives.
  • the present invention is also useful for the preparation of oligomeric compounds inco ⁇ orating at least one 2'-O-protected nucleoside. After inco ⁇ oration and appropriate deprotecton the 2'-O-protected nucleoside will be converted to a ribonucleoside at the position of inco ⁇ oration.
  • the number and position of the 2-ribonucleoside units in the final oligomeric compound can vary from one at any site or the stategy can be used to prepare up to a full 2'-OH modified oligomeric compound.
  • All 2'-O-protecting groups amenable to the synthesis of oligomeric compounds are included in the present invention.
  • a protected nucleoside is attached to a solid support by for example a succinate linker.
  • the oligonucleotide is elongated by repeated cycles of deprotecting the 5 '-terminal hydroxyl group, coupling of a further nucleoside unit, capping and oxidation (alternatively sulfurization).
  • the completed oligonucleotide is cleaved from the solid support with the removal of phosphate protecting groups and exocyclic amino protecting groups by teatment with an ammonia solution.
  • Some of the protecting groups used initially for oligoribonucleotide synthesis included tetahydropyran-1-yl and 4- ⁇ ethoxytetahydropyran-4-yl. These two groups are not compatible with all 5'-O- ⁇ rotecting groups so modified versions were used with 5'-DMT groups such as l-(2-fluorophenyl)-4-methoxypiperidin-4-yl (Fpmp).
  • Reese has identified a number of piperidine derivatives (like Fpmp) that are useful in the synthesis of oligoribonucleotides including l-[(chloro-4-methyl)phenyl]-4'-methoxypiperidin-4-yl (Reese et al., Tetahedron Lett., 1986, (27), 2291).
  • Another approach was to replace the standard 5'-DMT (dimethoxytityl) group with protecting groups that were removed under non-acidic conditions such as levulinyl and 9-fluorenylmethoxycarbonyl. Such groups enable the use of acid labile ⁇ -protecting groups for oligoribonucleotide synthesis.
  • the 2'-O-protecting groups can require special reagents for their removal such as for example the t-butyldimethylsilyl group is normally removed after all other cleaving/deprotecting steps by teatment of the oligomeric compound with tetabutylammonium fluoride (TB AF) .
  • TB AF tetabutylammonium fluoride
  • One group of researchers examined a number of 2'-O-protecting groups (Pitsch, S., Chimia, 2001, (55), 320-324.) The group examined fluoride labile and photolabile protecting groups that are removed using moderate conditions.
  • One photolabile group that was examined was the [2-(nitobenzyl)oxy]methyl (nbm) protecting group (Schwartz et al., Bioorg. Med.
  • RNA synthesis stategies that are presently being used commercially include 5'- O-DMT-2'-O-t-butyldimethylsilyl (TBDMS), 5'-O-DMT-2*-O-[l (2-fluorophenyl)-4- methoxypiperidin-4-yl] (FPMP), 2'-O-[(tiisopropylsilyl)oxy]methyl (2'-O-CH 2 -O- Si(iPr) 3 (TOM), and the 5'-O-silyl ether-2'-ACE (5'-O- bis(trimethylsiloxy)cyclododecyloxysilyl ether (DOD)-2'-O-bis(2-acetoxyethoxy)methyl (ACE).
  • RNA synthesis activator advertised to reduce coupling times especially with TOM and TBDMS chemistries. Such an activator would also be amenable to the present invention.
  • TBDMS 5'-O-DMT-2'-O-t-butyldimethylsilyl
  • TOM 2'-O-[(tiisopropylsilyl)oxy]methyl
  • DOD/ACE (5'-O-bis(trimethylsiloxy)cyclododecyloxysilyl ether-2'-O-bis(2- acetoxyethoxy)methyl
  • FPMP 5'-O-DMT-2'-O-[l(2-fluoro ⁇ henyl)-4-methoxypiperidin-4-yl] . All of the aforementioned RNA synthesis stategies are amenable to the present invention.
  • double standed oligonucleotide moieties have been shown in the art to modulate target expression and regulate tanslation as well as RNA processsing via an antisense mechanism.
  • the double-standed moietes may be subject to chemical modifications (Fire et al., Nature, 1998, 391, 806-811; Timmons and Fire, Nature 1998, 395, 854; Timmons et al., Gene, 2001, 263, 103-112; Tabara et al., Science, 1998, 282, 430-431; Montgomery et al., Proc. Natl. Acad. Sci.
  • the present invention comprehends the use of the oligomeric compounds and prefened targets identified herein in drug discovery efforts to elucidate relationships that exist between proteins and a disease state, phenotype, or condition.
  • These methods include detecting or modulating a target peptide comprising contacting a sample, tissue, cell, or organism with the oligomeric compounds of the present invention, measuring the nucleic acid or protein level of the target and/or a related phenotypic or chemical endpoint at some time after teatment, and optionally comparing the measured value to a non-teated sample or sample teated with a further oligomeric compound of the invention.
  • RNAi activity is evaluated according to existing literature (Elbashir et al., Nature (2001), 411, 494-498; Nishikura et al., Cell (2001), 107, 415-416; and Bass et al., Cell (2000), 101, 235-238.)
  • Targets of the invention can be a multistep process.
  • the process usually begins with the identification of a target nucleic acid whose function is to be modulated.
  • This target nucleic acid may be, for example, a cellular gene (or mRNA tanscribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent.
  • the targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result.
  • region is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic.
  • segments are defined as smaller or sub- portions of regions within a target nucleic acid.
  • Sites are defined as positions within a target nucleic acid. The terms region, segment, and site can also be used to describe an oligomeric compound of the invention such as for example a gapped oligomeric compound having 3 separate segments.
  • the tanslaton initiation codon is typically 5'- AUG (in tanscribed mRNA molecules; 5'-ATG in the conesponding DNA molecule), the tanslation initiation codon is also refened to as the "AUG codon," the "start codon” or the "AUG start codon”.
  • a minority of genes have a tanslation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo.
  • tanslation initiation codon and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for tanslation initiation in a particular cell type or tissue, or under a particular set of conditions.
  • start codon and "tanslaton initiation codon” refer to the codon or codons that are used in vivo to initiate tanslation of an mRNA tanscribed from a gene encoding a nucleic acid target, regardless of the sequence(s) of such codons. It is also known in the art that a tanslation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the conesponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).
  • start codon region and "tanslation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a tanslation initaton codon.
  • stop codon region and “tanslation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a tanslation termination codon.
  • the "start codon region” (or “tanslation initiation codon region”) and the “stop codon region” (or “tanslaton termination codon region”) are all regions which may be targeted effectively with the antisense oligomeric compounds of the present invention.
  • a prefened region is the intagenic region encompassing the tanslation initiation or termination codon of the open reading frame (ORF) of a gene.
  • target regions include the 5' untanslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the tanslation initiation codon, and thus including nucleotides between the 5' cap site and the tanslation initiation codon of an mRNA (or conesponding nucleotides on the gene), and the 3' untanslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the tanslation termination codon, and thus including nucleotides between the tanslation termination codon and 3' end of an mRNA (or conesponding nucleotides on the gene).
  • 5'UTR 5' untanslated region
  • 3'UTR 3' untanslated region
  • the 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' tiphosphate linkage.
  • the 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. It is also prefened to target the 5' cap region.
  • some eukaryotic mRNA tanscripts are directly tanslated, many contain one or more regions, known as "intons,” which are excised from a tanscript before it is tanslated.
  • exons The remaining (and therefore tanslated) regions are known as "exons" and are spliced together to form a contnuous mRNA sequence.
  • Targeting splice sites i.e., inton-exon junctions or exon-inton junctions, may also be particularly useful in situations where abenant splicing is implicated in disease, or where an ove ⁇ roduction of a particular splice product is implicated in disease.
  • Abenant fusion junctions due to reanangements or deletions are also prefened target sites.
  • mRNA tanscripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion tanscripts".
  • RNA tanscripts can be produced from the same genomic region of DNA. These alternative tanscripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other tanscripts produced from the same genomic DNA in either their start or stop position and contain both intonic and exonic sequences. Upon excision of one or more exon or inton regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants".
  • mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing.
  • These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant. It is also known in the art that variants can be produced through the use of alternative signals to start or stop tanscription and that pre-mRNAs and mRNAs can possess more that one start codon or stop codon. Variants that originate from a pre- mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA.
  • alternative stop variants of that pre-mRNA or mRNA.
  • One specific type of alternative stop variant is the “polyA variant” in which the multiple tanscripts produced result from the alternative selection of one of the "polyA stop signals" by the tanscription machinery, thereby producing tanscripts that terminate at unique polyA sites.
  • the types of variants described herein are also prefened target nucleic acids.
  • prefened target segments are hereinbelow refened to as "prefened target segments.”
  • prefened target segment is defined as at least an 8-nucleobase portion of a target region to which an active antisense oligomeric compound is targeted. While not wishing to be bound by theory, it is presently believed that these target segments represent accessible portions of the target nucleic acid for hybridization.
  • exemplary prefened antisense oligomeric compounds include oligomeric compounds that comprise at least the 8 consecutive nucleobases from the 5'-terminus of a targeted nucleic acid e.g.
  • nucleobases being a consecutive stetch of the same oligonucleotide beginning immediately upsteam of the 5 '-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains from about 8 to about 80 nucleobases).
  • prefened antisense oligomeric compounds are represented by oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 3 '-terminus of one of the illustative prefened antisense compounds (the remaining nucleobases being a consecutive stetch of the same oligonucleotide beginning immediately downsteam of the 3 '-terminus of the antsense compound which is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains from about 8 to about 80 nucleobases).
  • prefened antisense compounds illustated herein will be able, without undue experimentation, to identify further prefened antisense compounds.
  • antisense oligomeric compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.
  • a series of prefened compositions of nucleic acid duplexes comprising the antisense oligomeric compounds of the present invention and their complements can be designed for a specific target or targets.
  • the ends of the stands may be modified by the addition of one or more natural or modified nucleobases to form an overhang.
  • the sense stand of the duplex is then designed and synthesized as the complement of the antisense stand and may also contain modifications or additions to either terminus.
  • both stands of the duplex would be complementary over the cental nucleobases, each having overhangs at one or both termini.
  • a duplex comprising an antisense oligomeric compound having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure: cgagaggcggacgggaccgdTdT Antisense Strand dTdTgctctccgcctgccctggc Complement Strand RNA stands of the duplex can be synthesized by methods disclosed herein or purchased from various RNA synthesis companies such as for example Dharmacon Research Inc., (Lafayette, CO).
  • the complementary stands are annealed.
  • the single stands are aliquoted and diluted to a concentation of 50 uM. Once diluted, 30 uL of each stand is combined with 15uL of a 5X solution of annealing buffer.
  • the final concentation of the buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium acetate. The final volume is 75 uL.
  • This solution is incubated for 1 minute at 90°C and then centifuged for 15 seconds. The tube is allowed to sit for 1 hour at 37°C at which time the dsRNA duplexes are used in experimentation.
  • the final concentation of the dsRNA compound is 20 uM.
  • This solution can be stored frozen (-20°C) and freeze-thawed up to 5 times.
  • the desired synthetic duplexs are evaluated for their ability to modulate target expression.
  • they are teated with synthetc duplexs comprising at least one oligomeric compound of the invention.
  • synthetc duplexs comprising at least one oligomeric compound of the invention.
  • For cells grown in 96-well plates, wells are washed once with 200 ⁇ L OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then teated with 130 ⁇ L of OPTI-MEM-1 containing 12 ⁇ g/mL LIPOFECTIN (Gibco BRL) and the desired dsRNA compound at a final concentation of 200 nM.
  • prefened target segments identified herein may be employed in a screen for additional oligomeric compounds that modulate the expression of a target.
  • “Modulators” are those oligomeric compounds that decrease or increase the expression of a nucleic acid molecule encoding a target and which comprise at least an 8- nucleobase portion which is complementary to a prefened target segment.
  • the screening method comprises the steps of contacting a prefened target segment of a nucleic acid molecule encoding a target with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding a target.
  • the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding a target
  • the modulator may then be employed in further investigative studies of the function of a target, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.
  • the prefened target segments of the present invention may also be combined with their respective complementary antisense oligomeric compounds of the present invention to form stabilized double-standed (duplexed) oligonucleotides.
  • Hybridization occurs when two sequences come together with enough base complementarity to form a double standed region.
  • the source of the two sequences can be synthetic or native and can occur in a single stand when the stand has regions of self complementarity.
  • the prefened mechanism of pairing involves hydrogen bonding, which may be Watson- Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases) of the stands of oligomeric compounds or between an oligomeric compound and a target nucleic acid.
  • nucleobases complementary nucleoside or nucleotide bases
  • adenine and thymine are complementary nucleobases which pair through the format on of hydrogen bonds.
  • Hybridization can occur under varying circumstances.
  • An antisense oligomeric compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense oligomeric compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic teatment, and under conditions in which assays are performed in the case of in vitro assays.
  • stringent conditions refers to conditions under which an oligomeric compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditons are sequence-dependent and will vary with different circumstances and in the context of this invention, "stringent conditons” under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated. "Complementary,” as used herein, refers to the capacity for precise pairing of two nucleobases regardless of where the two are located.
  • a nucleobase at a certain position of an oligomeric compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, the target nucleic acid being a DNA, RNA, or oligonucleotide molecule
  • the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position.
  • the oligomeric compound and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other.
  • oligonucleotide and “complementary” are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleobases such that stable and specific binding occurs between the oligonucleotide and a target nucleic acid. It is understood in the art that the sequence of an antisense oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hai ⁇ in structure).
  • the antisense oligomeric compounds of the present invention comprise at least 70% sequence complementarity to a target region within the target nucleic acid, more preferably that they comprise 90%) sequence complementarity and even more preferably comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted.
  • an antisense oligomeric compound in which 18 of 20 nucleobases of the antisense oligomeric compound are complementary to a target region, and would therefore specifically hybridize would represent 90 percent complementarity.
  • the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases.
  • an antisense oligomeric compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8%) overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention.
  • Percent complementarity of an antisense oligomeric compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656).
  • prefened target segments may be employed in a screen for additional oligomeric compounds that modulate the expression of a selected protein.
  • Modules are those oligomeric compounds that decrease or increase the expression of a nucleic acid molecule encoding a protein and which comprise at least an 8-nucleobase portion which is complementary to a prefened target segment.
  • the screening method comprises the steps of contacting a prefened target segment of a nucleic acid molecule encoding a protein with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding a protein.
  • the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding a peptide
  • the modulator may then be employed in further investigative studies of the function of the peptide, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.
  • the prefened target segments of the present invention may also be combined with their respective complementary antisense oligomeric compounds of the present invention to form stabilized double-standed (duplexed) oligonucleotides.
  • double standed oligonucleotide moieties have been shown in the art to modulate target expression and regulate tanslaton as well as RNA processsing via an antsense mechanism.
  • the double-standed moietes may be subject to chemical modifications (Fire et al., Nature, 1998, 391, 806-811; Timmons and Fire, Nature 1998, 395, 854; Timmons et al., Gene, 2001, 263, 103-112; Tabara et al., Science, 1998, 282, 430-431 ; Montgomery et al., Proc. Natl Acad.
  • compositions comprising oligomeric compounds of the present invention can also be applied in the areas of drug discovery and target validation.
  • the present invention comprehends the use of the oligomeric compounds and prefened targets identified herein in drug discovery efforts to elucidate relationships that exist between proteins and a disease state, phenotype, or condition.
  • These methods include detecting or modulating a target peptide comprising contacting a sample, tissue, cell, or organism with the oligomeric compounds of the present invention, measuring the nucleic acid or protein level of the target and/or a related phenotypic or chemical endpoint at some time after teatment, and optonally comparing the measured value to a non-teated sample or sample teated with a further oligomeric compound of the invention.
  • RNAi activity is evaluated according to existing literature (Elbashir et al., Nature (2001), 411, 494-498; Nishikura et al., Cell (2001), 107, 415-416; and Bass et al., Cell (2000), 101, 235-238.)
  • compositions of oligomeric compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits.
  • antisense oligonucleotides which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.
  • the compositions of the present invention either alone or in combination with other oligomeric compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.
  • expression patterns within cells or tissues teated with one or more antsense oligomeric compounds are compared to contol cells or tissues not teated with antisense oligomeric compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds and or oligomeric compounds that affect expression patterns.
  • Examples of methods of gene expression analysis known in the art include DNA anays or microanays (Brazma and Vilo, FEBSLett, 2000, 480, 17-24; Celis, et al, FEBSLett, 2000, 480, 2-16), SAGE (serial analysis of gene expression)(Madden, et al, Drug Discov. Today, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, Methods Enzymol, 1999, 303, 258-72),
  • TOGA total gene expression analysis
  • compositions of the invention are useful for research and diagnostics in one sense because the oligomeric compounds of the compositions hybridize to nucleic acids encoding proteins.
  • oligonucleotides that are shown to hybridize with such efficiency and under such conditions as disclosed herein as to be effective protein inhibitors will also be effective primers or probes under conditions favoring gene amplification or detection, respectively.
  • primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding proteins and in the amplification of the nucleic acid molecules for detection or for use in further studies.
  • Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the invention with a nucleic acid can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of selected proteins in a sample may also be prepared. The specificity and sensitivity of antisense methodologies is also harnessed by those of skill in the art for therapeutic uses. Antisense oligomeric compounds have been employed as therapeutic moieties in the teatment of disease states in animals, including humans.
  • Antisense oligonucleotide drugs including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense oligomeric compounds can be useful therapeutic modalities that can be configured to be useful in teatment regimes for the teatment of cells, tissues and animals, especially humans.
  • an animal preferably a human, suspected of having a disease or disorder which can be teated by modulating the expression of a selected protein is teated by administering compositons of the invention in accordance with this invention.
  • the methods comprise the step of administering to the animal in need of teatment, a therapeutically effective amount of a protein inhibitor.
  • the protein inhibitors of the present invention effectively inhibit the activity of the protein or inhibit the expression of the protein.
  • the activity or expression of a protein in an animal is inhibited by about 10%.
  • the activity or expression of a protein in an animal is inhibited by about 30%. More preferably, the activity or expression of a protein in an animal is inhibited by 50%) or more.
  • the reduction of the expression of a protein may be measured in serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal.
  • the cells contained within the fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding a protein and/or the protein itself.
  • the compositons of the invention can be utilized in pharmaceutical compositions by adding an effective amount to a suitable pharmaceutically acceptable diluent or carrier. Use of the compositions and methods of the invention may also be useful prophylactically.
  • compositions of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or abso ⁇ tion.
  • Representative United States patents that teach the preparation of such uptake, distribution and/or abso ⁇ tion-assisting formulations include, but are not limited to, U.S.:
  • compositions of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administaton to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.
  • the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compositions of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.
  • prodrug indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions.
  • prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al, published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al
  • pharmaceutically acceptable salts refers to physiologically and pharmaceutically acceptable salts of the oligomeric compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.
  • the present invention also includes pharmaceutical compositions and formulations which include the compositions of the invention.
  • the pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic teatment is desired and upon the area to be teated.
  • Administation may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intatacheal, intanasal, epidermal and tansdermal), oral or parenteral.
  • Parenteral administation includes intavenous, intaarterial, subcutaneous, intaperitoneal or intamuscular injection or infusion; or intacranial, e.g., intathecal or intaventicular, administation.
  • Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administation.
  • Pharmaceutical compositions and formulations for topical administaton may include tansdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • Coated condoms, gloves and the like may also be useful.
  • the pharmaceutical formulations of the present invention which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry.
  • compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas.
  • the compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media.
  • Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextan.
  • the suspension may also contain stabilizers.
  • Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations.
  • the pharmaceutical compositions and formulations of the present invention may comprise one or more penetation enhancers, carriers, excipients or other active or inactive ingredients.
  • Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 ⁇ m in diameter.
  • Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase.
  • Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Patent 6,287,860, which is inco ⁇ orated herein in its entirety.
  • Formulations of the present invention include liposomal formulations.
  • liposome means a vesicle composed of amphiphilic lipids ananged in a spherical bilayer or bilayers.
  • Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered.
  • Cationic liposomes are positively charged liposomes which are believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that are pH-sensitive or negatively-charged are believed to entap DNA rather than complex with it. Both catonic and noncationic liposomes have been used to deliver DNA to cells.
  • Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when inco ⁇ orated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids.
  • sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety.
  • PEG polyethylene glycol
  • the pharmaceutical formulations and compositions of the present invention may also include surfactants.
  • surfactants used in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Patent 6,287,860, which is inco ⁇ orated herein in its entirety.
  • the present invention employs various penetation enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetation enhancers also enliance the permeability of lipophilic drugs.
  • Penetation enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Penetation enhancers and their uses are further described in U.S. Patent 6,287,860, which is inco ⁇ orated herein in its entirety. One of skill in the art will recognize that formulations are routinely designed according to their intended use, i.e. route of administation.
  • Prefened formulations for topical administation include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • Prefened lipids and liposomes include neutal (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g.
  • oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes.
  • oligonucleotides may be complexed to lipids, in particular to cationic lipids.
  • Prefened fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Patent 6,287,860, which is inco ⁇ orated herein in its entirety.
  • compositions and formulations for oral administation include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non- aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • Prefened oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetation enhancers surfactants and chelators.
  • Prefened surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Prefened bile acids/salts and fatty acids and their uses are further described in U.S. Patent 6,287,860, which is inco ⁇ orated herein in its entirety. Also prefened are combinations of penetaton enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly prefened combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetation enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether.
  • Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Patent 6,287,860, which is inco ⁇ orated herein in its entirety. Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 09/108,673 (filed July 1 , 1998), 09/315,298 (filed May 20, 1999) and 10/071,822, filed February 8, 2002, each of which is inco ⁇ orated herein by reference in their entirety.
  • compositions and formulations for parenteral, intathecal or intaventicular administation may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetation enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
  • sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetation enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
  • suitable additives such as, but not limited to, penetation enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
  • Certain embodiments of the invention provide pharmaceutical compositions containing one or more of the compositions of the invention and one or more other chemotherapeutic agents which function by a non-antisense mechanism.
  • chemotherapeutic agents include but are not limited to cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis- chloroethylnitosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethyl- melamine, pentamethylmelamine, mitoxantone, anisacrine, chlorambucil, methylcyclohexylnitrosurea, nitogen mustards, melphalan, cyclophosphamide, 6- mercaptopurine, 6-thioguanine, cytar
  • such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide).
  • chemotherapeutic agents e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide.
  • Anti-inflammatory drugs including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of compositions of the invention and other non-antisense drugs are also within the scope of this invention.
  • One or more compositions of the invention can be used in combination with other therapeutic agents to create a coctail as is cunently the stategy for certain viral infections.
  • therapeutically effective combination therapies may comprise the use of two or more compositions of the invention wherein the multiple compositions are targeted to a single or multiple nucleic acid targets. Numerous examples of antisense oligomeric compounds are known in the art. Two or more combined compounds may be used together or sequentially
  • Dosing The formulation of therapeutic compositions and their subsequent administaton (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be teated, with the course of teatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC 5 os found to be effective in in vitro and in vivo animal models.
  • dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentations of the drug in bodily fluids or tissues. Following successful teatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recunence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years. While the present invention has been described with specificity in accordance with certain of its prefened embodiments, the following examples serve only to illustate the invention and are not intended to limit the same.
  • Oligonucleotide and oligonucleoside synthesis The oligomeric compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkyiated derivatives.
  • the thiation reaction step time was increased to 180 sec and preceded by the normal capping step.
  • the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH OAc solution.
  • Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein inco ⁇ orated by reference.
  • Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein inco ⁇ orated by reference.
  • 3 '-Deoxy-3 '-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein inco ⁇ orated by reference.
  • Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein inco ⁇ orated by reference.
  • Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein inco ⁇ orated by reference.
  • 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein inco ⁇ orated by reference.
  • Phosphotiester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein inco ⁇ orated by reference.
  • Borano phosphate oligonucleotides are prepared as described in U.S. Patents
  • Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein inco ⁇ orated by reference.
  • Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein inco ⁇ orated by reference.
  • RNA synthesis chemistry is based on the selective inco ⁇ oration of various protecting groups at stategic intermediary reactons.
  • a useful class of protecting groups includes silyl ethers.
  • bulky silyl ethers are used to protect the 5 '-hydroxyl in combination with an acid-labile orthoester protecting group on the 2 '-hydroxyl.
  • This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps.
  • RNA oligonucleotides were synthesized. RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5 '-direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3 '-end of the chain is covalently attached to a solid support.
  • the nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5 '-end of the first nucleoside.
  • the support is washed and any umeacted 5 '-hydroxyl groups are capped with acetic anhydride to yield 5 '-acetyl moieties.
  • the linkage is then oxidized to the more stable and ultimately desired P(V) linkage.
  • the 5 '-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.
  • the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-l,l-dithiolate tihydrate (S 2 Na 2 ) in DMF.
  • the deprotection solution is washed from the solid support- bound oligonucleotide using water.
  • the support is then teated with 40% methylamine in water for 10 minutes at 55 °C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2 '-groups.
  • the oligonucleotides can be analyzed by anion exchange HPLC at this stage.
  • the 2 '-orthoester groups are the last protecting groups to be removed.
  • the ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, CO), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is teated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters.
  • the resulting 2-ethyl-hydroxyl substituents on the orthoester are less electon withdrawing than the acetylated precursor.
  • the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the final RNA oligonucleotide product. Additionally, methods of RNA synthesis are well known in the art (Scaringe, S.
  • RNA antisense oligomeric compounds (RNA oligonucleotides) of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, CO). Once synthesized, complementary RNA antisense oligomeric compounds can then be annealed by methods known in the art to form double standed (duplexed) antisense oligomeric compounds.
  • duplexes can be formed by combining 30 ⁇ l of each of the complementary stands of RNA oligonucleotides (50 uM RNA oligonucleotide solution) and 15 ⁇ l of 5X annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 minute at 90°C, then 1 hour at 37°C.
  • 5X annealing buffer 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate
  • the resulting duplexed antisense oligomeric compounds can be used in kits, assays, screens, or other methods to investigate the role of a target nucleic acid.
  • Chimeric Oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end” type wherein the "gap” segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as “gapmers” or gapped oligonucleotides.
  • Oligonucleotides of the second type are also known in the art as “hemimers” or "wingmers”. [2'-O-Me] ⁇ [2'-deoxy] ⁇ [2'-O-Me] Chimeric Phosphorothioate Oligonucleotides Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above.
  • Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxyMtyl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings.
  • the standard synthesis cycle is modified by inco ⁇ orating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite.
  • the fully protected oligonucleotide is cleaved from the support and deprotected in concentated ammonia (NH 4 OH) for 12-16 hr at 55°C.
  • the deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced in vacuo and analyzed spetophotometically for yield and for purity by capillary electrophoresis and by mass spectometry.
  • (methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O- (methoxyethyl) amidites for the 2'-O-mefhyl amidites, oxidation with iodine to generate the phosphodiester intemucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate intemucleotide linkages for the center gap.
  • chimeric oligonucleotides chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein inco ⁇ orated by reference.
  • a series of nucleic acid duplexes comprising the antisense oligomeric compounds of the present invention and their complements can be designed to target a target.
  • the ends of the stands may be modified by the addition of one or more natural or modified nucleobases to fomi an overhang.
  • the sense stand of the dsRNA is then designed and synthesized as the complement of the antisense stand and may also contain modifications or additions to either terminus.
  • both stands of the dsRNA duplex would be complementary over the cental nucleobases, each having overhangs at one or both termini.
  • a duplex comprising an antisense stand having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure: cgagaggcggacgggaccgTT Antisense 1 1 1 1 1 1 I I I I 1 1 1 1 1 1 1 strand TTgctctccgcctgccctggc Complement Strand RNA stands of the duplex can be synthesized by methods disclosed herein or purchased from Dharmacon Research Inc., (Lafayette, CO). Once synthesized, the complementary stands are annealed. The single stands are aliquoted and diluted to a concentation of 50 uM.
  • duplexed antisense oligomeric compounds are evaluated for their ability to modulate a target expression.
  • they are teated with duplexed antisense oligomeric compounds of the invention.
  • OPTI-MEM-1 reduced-serum medium Gibco BRL
  • 130 ⁇ L of OPTI-MEM-1 containing 12 g/mL LIPOFECTIN Gibco BRL
  • the desired duplex antisense oligomeric compound After 5 hours of teatment, the medium is replaced with fresh medium.
  • RNA is isolated and target reduction measured by RT-PCR.
  • the duplexed oligomeric compounds are evaluated in HeLa cells (American Type Culture Collection, Manassas VA). Culture methods used for HeLa cells are available from the ATCC and may be found, for example, at http://www.atcc.org.
  • wells are washed once with 200 ⁇ L OPTI-MEM-1 reduced-serum medium (Gibco BRL) and are teated with 130 ⁇ L of OPTI-MEM-1 containing 12 ⁇ g/mL LIPOFECTINTM (Gibco BRL) and the dsRNA at the desired concentation.
  • Example 7 Oligonucleotide Isolation After cleavage from the contolled pore glass solid support and deblocking in concentated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH 4 OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electospray mass spectoscopy (molecular weight determination) and by capillary gel electophoresis and judged to be at least 70% full length material.
  • Oligonucleotide Synthesis - 96 Well Plate Format Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester intemucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate intemucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile.
  • Standard base-protected beta-cyanoethyl- diiso-propyl phosphoramidites were purchased from commercial vendors (e.g. PE- Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ).
  • Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyldiisopropyl phosphoramidites. Oligonucleotides were cleaved from support and deprotected with concentated
  • Oligonucleotide Analysis using 96-Well Plate Format The concentation of oligonucleotde in each well was assessed by dilution of samples and UV abso ⁇ tion spectoscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACETM MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACETM 5000, ABI 270). Base and backbone compositon was confirmed by mass analysis of the oligomeric compounds utilizing electospray- mass spectoscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the oligomeric compounds on the plate were at least 85% full length.
  • oligomeric compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the, target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or
  • T-24 cells The human tansitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA).
  • T-24 cells were routinely cultured in complete McCoy's 5 A basal media (Invitogen Co ⁇ oration, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitogen Co ⁇ oration, Carlsbad, CA), penicillin 100 units per mL, and steptomycin 100 micrograms per mL (Invitogen Co ⁇ oration, Carlsbad, CA).
  • Cells were routinely passaged by trypsinization and dilution when they reached 90%> confluence. Cells were seeded into 96-well plates (Falcon-Primaria #353872) at a density of 7000 cells/well for use in RT-PCR analysis.
  • A549 cells The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitogen Co ⁇ oration, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitogen Co ⁇ oration, Carlsbad, CA), penicillin 100 units per mL, and steptomycin 100 micrograms per mL (Invitogen Co ⁇ oration, Carlsbad, CA). Cells were routinely passaged by typsinization and dilution when they reached 90% confluence.
  • NHDF cells Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics
  • HEK cells Human embryonic keratinocytes (HEK) were obtained from the Clonetics Co ⁇ oration (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Co ⁇ oration, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.
  • oligomeric compounds Treatment with oligomeric compounds: When cells reached 65-75% confluency, they were teated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 ⁇ L OPTI-MEMTM-l reduced-serum medium (Invitogen Co ⁇ oration, Carlsbad, CA) and then teated with 130 ⁇ L of OPTI-MEMTM-l containing 3.75 ⁇ g/mL LIPOFECTINTM (Invitogen
  • the positive contol oligonucleotide is selected from either ISIS 13920 (TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 3) which is targeted to human H-ras, or ISIS 18078, (GTGCGCGCGAGCCCGAAATC, SEQ ID NO: 4) which is targeted to human Jun-N-terminal kinase-2 (JNK2).
  • Both contols are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone.
  • the positive contol oligonucleotide is ISIS 15770, ATGCATTCTGCCCCCA- AGGA, SEQ ID NO: 5, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf.
  • the concentations of antisense oligonucleotides used herein are from 50 nM to 300 nM.
  • RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA.
  • the prefened method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are well known in the art. Northern blot analysis is also routine in the art.
  • PCR Real-time quantitative
  • ABI PRISMTM 7600, 7700, or 7900 Sequence Detection System available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.
  • Protein levels of a target can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme- linked immunosorbent assay (ELISA) or fluorescence-activated cell sorting (FACS).
  • Antibodies directed to a target can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Co ⁇ oration, Birmingham, MI), or can be prepared via conventional monoclonal or polyclonal antibody generation methods well known in the art.
  • Phenotypic assays Once a target inhibitors have been identified by the methods disclosed herein, the oligomeric compounds are further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the teatment of a particular disease state or condition. Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of a target in health and disease.
  • phenotypic assays which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, OR; PerkinElmer, Boston, MA), protein-based assays including enzymatic assays (Panvera, LLC, Madison, WI; BD Biosciences, Franklin Lakes, NJ; Oncogene Research Products, San Diego, CA), cell regulation, signal tansduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, MI), xriglyceride accumulation (Sigma-Aldrich, St.
  • angiogenesis assays i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies
  • a target inhibitors identified from the in vitro studies as well as contol compounds at optimal concentatons which are determined by the methods described above.
  • teated and unteated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.
  • Phenotypic endpoints include changes in cell mo ⁇ hology over time or teatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest. Analysis of the geneotype of the cell (measurement of the expression of one or more of the genes of the cell) after teatment is also used as an indicator of the efficacy or potency of the a target inhibitors. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both teated and unteated cells. In vivo studies The individual subjects of the in vivo studies described herein are warm-blooded vertebrate animals, which includes humans.
  • Volunteers receive either the a target inhibitor or placebo for eight week period with biological parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any teatment), end (after the final teatment), and at regular intervals during the study period.
  • biological parameters associated with the indicated disease state or condition include the levels of nucleic acid molecules encoding a target or a target protein levels in body fluids, tissues or organs compared to pre-tieatment levels.
  • Other measurements include, but are not limited to, indices of the disease state or condition being teated, body weight, blood pressure, serum liters of pharmacologic indicators of disease or toxicity as well as ADME (abso ⁇ tion, distribution, metabolism and excretion) measurements.
  • Information recorded for each patient includes age (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating (some/moderate/great) and number and type of previous teatment regimens for the indicated disease or condition.
  • Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and a target inhibitor teatment. In general, the volunteers teated with placebo have little or no response to teatment, whereas the volunteers teated with the a target inhibitor show positive tends in their disease state or conditon index at the conclusion of the study.
  • RNA Isolation Poly(A)+ mRNA isolation Poly(A)+ mRNA was isolated according to Miura et al, (Clin. Chem., 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are routine in the art. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 ⁇ L cold PBS. 60 ⁇ L lysis buffer (10 M Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes.
  • lysis buffer (10 M Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex
  • RNA Isolation Total RNA was isolated using an RNEASY 96TM kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 ⁇ L cold PBS.
  • Buffer RLT 150 ⁇ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 ⁇ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then tansfened to the RNEASY 96TM well plate attached to a QIAVACTM manifold fitted with a waste collection tay and attached to a vacuum source. Vacuum was applied for 1 minute. 500 ⁇ L of Buffer RW1 was added to each well of the RNEASY 96TM plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500 ⁇ L of Buffer RW1 was added to each well of the RNEASY 96TM plate and the vacuum was applied for 2 minutes.
  • the repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is tansfened to the robot deck where the pipetting, DNase teatment and elution steps are carried out.
  • PCR using the ABI PRISMTM 7600, 7700, or 7900 Sequence Detection System (PE- Applied Biosystems, Foster City, CA) according to manufacturer's instructions.
  • ABI PRISMTM 7600, 7700, or 7900 Sequence Detection System PE- Applied Biosystems, Foster City, CA
  • This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time.
  • PCR polymerase chain reaction
  • products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes.
  • a reporter dye e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA
  • a quencher dye e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA
  • TAMRA obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA
  • annealing of the probe to the target sequence creates a substate that can be cleaved by the 5'-exonuclease activity of Taq polymerase.
  • cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated.
  • additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISMTM Sequence Detection System.
  • a series of parallel reactions containing serial dilutions of mRNA from unteated contol samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide teatment of test samples.
  • primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction.
  • GAPDH amplification reaction In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concunently in a single sample. In this analysis, mRNA isolated from unteated cells is serially diluted.
  • Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single- plexing"), or both (multiplexing).
  • primer-probe sets specific for GAPDH only target gene only
  • target gene only target gene only
  • multiplexing target gene only
  • standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and conelation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10%) of their conesponding values generated from the single-plexed samples, the primer- probe set specific for that target is deemed multiplexable.
  • Other methods of PCR are also known in the art. PCR reagents were obtained from Invitogen Co ⁇ oration, (Carlsbad, CA).
  • RT-PCR reactions were carried out by adding 20 ⁇ L PCR cocktail (2.5x PCR buffer minus MgCl 2 , 6.6 mM MgCl 2 , 375 ⁇ M each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNAse inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse tanscriptase, and 2.5x ROX dye) to 96-well plates containing 30 ⁇ L total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48°C.
  • PCR cocktail 2.5x PCR buffer minus MgCl 2 , 6.6 mM MgCl 2 , 375 ⁇ M each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units
  • Example 15 Northern blot analysis of a target mRNA levels
  • cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOLTM (TEL-TEST "B” Inc., Friendswood, TX).
  • Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH).
  • STRATALINKERTM UV Crosslinker 2400 Statagene, Inc, La Jolla, CA
  • QUICKHYBTM hybridization solution Statagene, La Jolla, CA
  • a human a target specific primer probe set is prepared by PCR
  • membranes are stripped and probed for human glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).
  • GPDH glyceraldehyde-3 -phosphate dehydrogenase
  • Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGERTM and IMAGEQUANTTM Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in unteated contols.
  • oligomeric compounds Inhibition of human a target expression by oligomeric compounds
  • a series of oligomeric compounds are designed to target different regions of the human target RNA.
  • the oligomeric compounds are analyzed for their effect on human target mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments.
  • the target regions to which these prefened sequences are complementary are herein refened to as "prefened target segments" and are therefore prefened for targeting by oligomeric compounds of the present invention.
  • the sequences represent the reverse complement of the prefened oligomeric compounds.
  • oligomeric compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other short oligomeric compounds which hybridize to at least a portion of the target nucleic acid.
  • GCS external guide sequence
  • Western blot analysis of target protein levels Western blot analysis (immunoblot analysis) is carried out using standard methods.
  • Cells are harvested 16-20 h after oligonucleotide teatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16%) SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and tansfened to membrane for western blotting. Appropriate primary antibody directed to a target is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGERTM (Molecular Dynamics, Sunnyvale CA).
  • MCF-7 cells The human breast carcinoma cell line MCF-7 is obtained from the American Type Culture Collection (Manassas, VA). These cells contain a wild-type p53 gene. MCF-7 cells are routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10%> fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reach 90%> confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for teatment with the oligomeric compounds of the invention.
  • HepB3 cells The human hepatoma cell line HepB3 (Hep3B2.1-7) is obtained from the American Type Culture Collection (ATCC-ATCC Catalog # HB-8064) (Manassas, VA). This cell line was initially derived from a hepatocellular carcinoma of an 8-yr-old black male. The cells are epithelial in mo ⁇ hology and are tumorigenic in nude mice.
  • HepB3 cells are routinely cultured in Minimum Essential Medium (MEM) with Earle's Balanced Salt Solution, 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate (ATCC #20-2003, Manassas, VA) and with 10% heat-inactivated fetal bovine serum (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence.
  • T-24 cells The tansitional cell bladder carcinoma cell line T-24 is obtained from the American Type Culture Collection (ATCC) (Manassas, VA).
  • T-24 cells are routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10%) fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and steptomycin 100 ⁇ g/mL (Gibco/Life Technologies, Gaithersburg, MD).
  • Cells are routinely passaged by trypsinization and dilution when they reach 90% confluence. Cells are seeded into 96-well plates (Falcon- Primaria #3872) at a density of 7000 cells/well for teatment with the compound of the invention.
  • A549 cells The human lung carcinoma cell line A549 is obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells are routinely cultured in
  • DMEM basal media Gibco/Life Technologies, Gaithersburg, MD
  • fetal calf serum Gibco/Life Technologies, Gaithersburg, MD
  • penicillin 100 units per mL penicillin 100 units per mL
  • steptomycin 100 ⁇ g/mL Gabco/Life Technologies, Gaithersburg, MD.
  • Cells are routinely passaged by trysinization and dilution when they reach 90% confluence.
  • Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for teatment with the compound of the invention.
  • Primary mouse hepatocytes Primary mouse hepatocytes are prepared from CD-I mice purchased from Charles River Labs.
  • hepatocytes are routinely cultured in Hepatocyte Attachment Media (Invitrogen Life Technologies, Carlsbad, CA) supplemented with 10%) Fetal Bovine Serum (Invitogen Life Technologies, Carlsbad, CA), 250 nM dexamethasone (Sigma- Aldrich Co ⁇ oration, St. Louis, MO), 10 nM bovine insulin (Sigma-Aldrich Co ⁇ oration, St. Louis, MO).
  • Cells are seeded into 96-well plates (Falcon-Primaria #353872, BD Biosciences, Bedford, MA) at a density of 4000-6000 cells/well for teatment with the oligomeric compounds of the invention.
  • Liposome-mediated treatment with oligomeric compounds of the invention When cells reach the desired confluency, they can be teated with the oligomeric compounds of the invention by liposome-mediated tansfection.
  • OPTI-MEMTM- 1 reduced-semm medium For cells grown in 96- well plates, wells are washed once with 200 ⁇ L OPTI-MEMTM- 1 reduced-semm medium (Gibco BRL) and then teated with 100 ⁇ L of OPTI-MEMTM-l containing 2.5 ⁇ g/mL LIPOFECTINTM (Gibco BRL) and the oligomeric compounds of the invention at the desired final concentation. After 4 hours of teatment, the medium is replaced with fresh medium. Cells are harvested 16 hours after teatment with the oligomeric compounds of the invention for target mRNA expression analysis by real-time PCR.
  • Electroporation-mediated treatment with oligomeric compounds of the invention When the cells reach the desired confluency, they can be teated with the oligomeric compounds of the invention by electo ⁇ oration.
  • Cells are electoporated in the presence of the desired concentation of an oligomeric compound of the invention in 1 mm cuvettes at a density of 1 X 10 7 cells/mL, a voltage of 75 V and a pulse length of 6 ms. Following the delivery of the electrical pulse, cells are replated for 16 to 24 hours. Cells are then harvested for target mRNA expression analysis by real-time PCR.
  • Apoptosis assay Caspase-3 activity is evaluated with an fluorometic HTS Caspase-3 assay (Oncogene Research Products, San Diego, CA) that detects cleavage after aspartate residues in the peptide sequence (DEVD).
  • the DEVD substate is labeled with a fluorescent molecule, which exhibits a blue to green shift in fluorescence upon cleavage.
  • Active caspase-3 in teated cells is measured by this assay according to the manufacturer's instructions. Following teatment with the oligomeric compounds of the invent on, 50 ⁇ L of assay buffer is added to each well, followed by additon 20 ⁇ L of the caspase-3 fluorescent substate conjugate. Data are obtained in triplicate.
  • Fluorescence in wells is immediately detected (excitation/emission 400/505 nm) using a fluorescent plate reader (SpectaMAX GeminiXS, Molecular Devices, Sunnyvale, CA). The plate is covered and incubated at 37°C for an additional three hours, after which the fluorescence is again measured (excitation emission 400/505 nm). The value at time zero is subtacted from the measurement obtained at 3 hours. The measurement obtained from the unteated contol cells is designated as 100% activity.
  • Cell proliferation and viability assay are measured using the CyQuant Cell Proliferation Assay Kit (Molecular Probes, Eugene, OR) utilizing the CyQuant GR green fluorescent dye which exhibits stong fluorescence enhancement when bound to cellular nucleic acids.
  • the assay is performed according to the manufacturer's instructions. After the teatment with one or more oligomeric compounds of the invention, the microplate is gently inverted to remove the medium from the wells, which are each washed once with 200 ⁇ L of phosphate-buffered saline. Plates are frozen at -70°C and then thawed. A volume of 200 ⁇ L of the CyQUANT GR dye/cell-lysis buffer is added to each well.
  • the microplate is incubated for 5 minutes at room temperature, protected from light. Data are obtained in triplicate. Fluorescence in wells is immediately detected (excitation emission 480/520 nm) using a fluorescent plate reader (SpectaMAX GeminiXS, Molecular Devices, Sunnyvale, CA). The measurement obtained from the unteated contol cells is designated as 100% activity.
  • Example 23 Leptin-deficient mice a model of obesity and diabetes (ob/ob mice) Leptin is a hormone produced by fat that regulates appetite. Deficiencies in this hormone in both humans and non-human animals leads to obesity, ob/ob mice have a mutation in the leptin gene which results in obesity and hyperglycemia. As such, these mice are a useful model for the investigation of obesity and diabetes and teatnents designed to teat these conditions, ob/ob mice have higher circulating levels of insulin and are less hyperglycemic than db/db mice, which harbor a mutation in the leptin receptor.
  • the oligomeric compounds of the invention are tested in the ob/ob model of obesity and diabetes. Seven-week old male C57B1/6 J-Lepr ob/ob mice (Jackson Laboratory, Bar).
  • mice are fed a diet with a fat content of 10-15% and are subcutaneously injected with the oligomeric compounds of the invention or a contol compound at a dose of 25 mg/kg two times per week for 4 weeks.
  • Saline-injected animals, leptin wildtype littermates (i.e. lean littermates) and ob/ob mice fed a standard rodent diet serve as contols.
  • mice are sacrificed and target levels are evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT).
  • RNA isolation and target mRNA expression level quantitation are performed as described by other examples herein.
  • the ob/ob mice are further evaluated at the end of the teatment period for serum lipids, serum free fatty acids, serum cholesterol (CHOL), liver tiglycerides, fat tissue tiglycerides and liver enzyme levels.
  • Hepatic steatosis or clearing of lipids from the liver, is assessed by measuring the liver tiglyceride content.
  • Hepatc steatosis is assessed by routine histological analysis of frozen liver tissue sections stained with oil red O stain, which is commonly used to visualize lipid deposits, and counterstained with hematoxylin and eosin, to visualize nuclei and cytoplasm, respectively.
  • Plasma glucose is measured at the start of the teatment and after 2 weeks and 4 weeks of teatment.
  • Plasma insulin is similarly measured at the beginning of the teatment, and following at 2 weeks and at 4 weeks of teatment.
  • Glucose and insulin tolerance tests are also administered in fed and fasted mice. Mice receive intaperitoneal injections of either glucose or insulin, and the blood glucose and insulin levels are measured before the insulin or glucose challenge and at 15, 20 or 30 minute intervals for up to 3 hours.
  • the respiratory quotient and oxygen consumption of the mice are also measured.
  • the ob/ob mice that received teatment are further evaluated at the end of the teatment period for the effects of target inhibition on the expression genes that participate in lipid metabolism, cholesterol biosynthesis, fatty acid oxidation, fatty acid storage, gluconeogenesis and glucose metabolism.
  • genes include, but are not limited to, HMG-CoA reductase, acetyl-CoA carboxylase 1 and acetyl-CoA carboxylase 2, camitine palmitoyltansferase I and glycogen phosphorylase, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 1, lipoprotein lipase and hormone sensitive lipase.
  • mRNA levels in liver and white and brown adipose tissue are quantitated by real- time PCR as described in other examples herein, employing primer-probe sets that are generated using published sequences of each gene of interest.
  • Leptin receptor-deficient mice a model of obesity and diabetes (db/db mice) Leptin is a hormone produced by fat that regulates appetite. Deficiencies in this hormone in both humans and non-human animals leads to obesity, db/db mice have a mutation in the leptin receptor gene which results in obesity and hyperglycemia. As such, these mice are a useful model for the investigation of obesity and diabetes and teatnents designed to teat these conditions, db/db mice, which have lower circulating levels of insulin and are more hyperglycemic than ob/ob mice which harbor a mutation in the leptin gene, are often used as a rodent model of type 2 diabetes.
  • oligomeric compounds of the present invention are tested in the db/db model of obesity and diabetes.
  • Seven-week old male C57B1/6J-Lepr db/db mice (Jackson Laboratory, Bar Harbor, ME) are fed a diet with a fat content of 15-20% and are subcutaneously injected with one or more of the oligomeric compounds of the invention or a contol compound at a dose of 25 mg/kg two times per week for 4 weeks.
  • Saline-injected animals, leptin receptor wildtype littermates (i.e. lean littermates) and db/db mice fed a standard rodent diet serve as contols.
  • mice are sacrificed and target levels are evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT).
  • RNA isolation and target mRNA expression level quantitation are performed as described by other examples herein.
  • mice are sacrificed and target levels are evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT).
  • RNA isolation and target mRNA expression level quantitation are performed as described by other examples herein.
  • the db/db mice that receive teatment are further evaluated at the end of the teatment period for semm lipids, semm free fatty acids, serum cholesterol (CHOL), liver tiglycerides, fat tissue tiglycerides and liver enzyme levels.
  • Hepatic steatosis or clearing of lipids from the liver, is assessed by measuring the liver tiglyceride content.
  • Hepatic steatosis is also assessed by routine histological analysis of frozen liver tissue sections stained with oil red O stain, which is commonly used to visualize lipid deposits, and counterstained with hematoxylin and eosin, to visualize nuclei and cytoplasm, respectively.
  • the effects of target inhibition on glucose and insulin metabolism are also evaluated in the db/db mice teated with the oligomeric compounds of the invention.
  • Plasma glucose is measured at the start of the teatment and after 2 weeks and 4 weeks of teatment. Plasma insulin is similarly measured at the beginning of the teatment, and following 2 weeks and 4 weeks of teatment.
  • Glucose and insulin tolerance tests are also administered in fed and fasted mice. Mice receive intaperitoneal injections of either glucose or insulin, and the blood glucose levels are measured before the insulin or glucose challenge and 15, 30, 60, 90 and 120 minutes following the injection. To assess the metabolic rate of db/db mice teated with the oligomeric compounds of the invention, the respiratory quotient and oxygen consumption of the mice is also measured.
  • the db/db mice that receive teatment are further evaluated at the end of the teatment period for the effects of target inhibition on the expression genes that participate in lipid metabolism, cholesterol biosynthesis, fatty acid oxidation, fatty acid storage, gluconeogenesis and glucose metabolism.
  • These genes include, but are not limited to, HMG-CoA reductase, acetyl-CoA carboxylase 1 and acetyl-CoA carboxylase 2, carnitine palmitoyltansferase I and glycogen phosphorylase, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 1, lipoprotein lipase and hormone sensitive lipase.
  • mRNA levels in liver and white and brown adipose tissue are quantitated by realtime PCR as described in other examples herein, employing primer-probe sets that are generated using published sequences of each gene of interest.
  • Example 25 Lean mice on a standard rodent diet C57B1/6 mice are maintained on a standard rodent diet and are used as contol (lean) animals.
  • the oligomeric compounds of the invention are tested in normal, lean animals. Seven- week old male C57B1/6 mice are fed a diet with a fat content of 4% and are subcutaneously injected with one or more of the oligomeric compounds of the invention or contol compounds at a dose of 25 mg/kg two times per week for 4 weeks. Saline-injected animals serve as a contol. After the teatment period, mice are sacrificed and target levels are evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT). RNA isolation and target mRNA expression level quantitation are performed as described by other examples herein.
  • mice are sacrificed and target levels are evaluated in liver, brown adipose tissue (BAT) and white adipose tissue (WAT).
  • RNA isolation and target mRNA expression level quantitation are performed as described by other examples herein.
  • the lean mice that receive teatment are further evaluated at the end of the teatment period for semm lipids, semm free fatty acids, semm cholesterol (CHOL), liver tiglycerides, fat tissue tiglycerides and liver enzyme levels. Hepatic steatosis, or clearing of lipids from the liver, is assessed by measuring the liver tiglyceride content.
  • Hepatic steatosis is also assessed by routine histological analysis of frozen liver tissue sections stained with oil red O stain, which is commonly used to visualize lipid deposits, and counterstained with hematoxylin and eosin, to visualize nuclei and cytoplasm, respectively.
  • the effects of target inhibition on glucose and insulin metabolism are also evaluated in the lean mice teated with the oligomeric compounds of the invention. Plasma glucose is measured at the start of the teatment and after 2 weeks and 4 weeks of teatment. Plasma insulin is similarly measured at the beginning of the teatment, and following 2 weeks and 4 weeks of teatment. Glucose and insulin tolerance tests are also administered in fed and fasted mice.
  • mice receive intaperitoneal injections of either glucose or insulin, and the blood glucose levels are measured before the insulin or glucose challenge and 15, 30, 60, 90 and 120 minutes following the injection.
  • the respiratory quotient and oxygen consumption of the mice is also measured.
  • the lean mice that received teatment are further evaluated at the end of the teatment period for the effects of target inhibition on the expression genes that participate in lipid metabolism, cholesterol biosynthesis, fatty acid oxidation, fatty acid storage, gluconeogenesis and glucose metabolism.
  • genes include, but are not limited to, HMG-CoA reductase, acetyl-CoA carboxylase 1 and acetyl-CoA carboxylase 2, carnitine palmitoyltansferase I and glycogen phosphorylase, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 1, lipoprotein lipase and hormone sensitive lipase.
  • mRNA levels in liver and white and brown adipose tissue are quantitated by realtime PCR as described in other examples herein, employing primer-probe sets that are generated using published sequences of each gene of interest. It is intended that each publication refened to in this application, including but not limited to books, references, patents and patent applications, be inco ⁇ orated herein in their entirety.

Abstract

L'invention concerne des compositions bicaténaires dans lesquelles le premier brin comprend trois régions différentes et le second brin est un ARN natif. Chaque région possède des fractions de sucre de ribofuranosyle natif ou modifié qui diffèrent de celles des deux autres régions. Au moins une partie du premier composé oligomère est complémentaire d'une cible d'acide nucléique et hybride celle-ci. L'invention concerne également des procédés permettant de moduler l'expression génique au moyen des composés oligomères modifiés et des compositions de composés oligomères.
PCT/US2004/017522 1996-06-06 2004-06-03 Compositions chimeriques oligomeres a breche WO2005121368A1 (fr)

Priority Applications (36)

Application Number Priority Date Filing Date Title
PCT/US2004/017522 WO2005121368A1 (fr) 2004-06-03 2004-06-03 Compositions chimeriques oligomeres a breche
CA002569036A CA2569036A1 (fr) 2004-06-03 2004-06-03 Compositions chimeriques oligomeres a breche
JP2007515019A JP2008501335A (ja) 2004-06-03 2004-06-03 キメラギャップ化オリゴマー組成物
AU2004320622A AU2004320622B2 (en) 2004-06-03 2004-06-03 Chimeric gapped oligomeric compositions
US11/569,941 US20080261904A1 (en) 2004-06-03 2004-06-03 Chimeric Gapped Oligomeric Compounds
EP04754188A EP1766052A4 (fr) 2004-06-03 2004-06-03 Compositions chimeriques oligomeres a breche
EP05757763A EP1766071A4 (fr) 2004-06-03 2005-06-02 Composition a double brin comprenant des brins différentiellement modifiés utilisés dans la modulation génétique
JP2007515521A JP2008501693A (ja) 2004-06-03 2005-06-02 遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
CA002568735A CA2568735A1 (fr) 2004-06-03 2005-06-02 Composition a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
AU2005252662A AU2005252662B2 (en) 2004-06-03 2005-06-02 Double strand compositions comprising differentially modified strands for use in gene modulation
EP05757632A EP1765416A4 (fr) 2004-06-03 2005-06-02 Compositions a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
PCT/US2005/019217 WO2005121370A2 (fr) 2004-06-03 2005-06-02 Composes oligomeres facilitant la charge 'risc'
PCT/US2005/019220 WO2005121372A2 (fr) 2004-06-03 2005-06-02 Compositions a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
US11/569,955 US20090048192A1 (en) 2004-06-03 2005-06-02 Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP2007515522A JP2008501694A (ja) 2004-06-03 2005-06-02 遺伝子調節の使用のために個別に修飾された鎖を有する二本鎖組成物
US11/569,929 US20070275921A1 (en) 1996-06-06 2005-06-02 Oligomeric Compounds That Facilitate Risc Loading
EP05756325A EP1765415A4 (fr) 2004-06-03 2005-06-02 Composes oligomeres facilitant la charge "risc"
AU2005252663A AU2005252663B2 (en) 2004-06-03 2005-06-02 Double strand compositions comprising differentially modified strands for use in gene modulation
PCT/US2005/019219 WO2005121371A2 (fr) 2004-06-03 2005-06-02 Composition a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
US11/569,931 US20080119427A1 (en) 1996-06-06 2005-06-02 Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
CA002569419A CA2569419A1 (fr) 2004-06-03 2005-06-02 Compositions a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
US11/565,858 US20070167392A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,781 US20070185046A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,816 US20070179107A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,794 US20070173474A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,773 US20070123484A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,785 US20070185047A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,841 US20070167391A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,804 US20070173475A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,799 US20070179106A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,823 US20070179108A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,839 US20070179109A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,817 US20070167390A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,833 US20070172948A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,770 US20070166734A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US14/804,743 US20160017328A1 (en) 2004-06-03 2015-07-21 Double strand compositions comprising differentially modified strands for use in gene modulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/017522 WO2005121368A1 (fr) 2004-06-03 2004-06-03 Compositions chimeriques oligomeres a breche

Related Child Applications (15)

Application Number Title Priority Date Filing Date
PCT/US2004/017485 Continuation-In-Part WO2005120230A2 (fr) 1996-06-06 2004-06-03 Produits de synthese d'arnsi modifies en position
US11/565,794 Continuation-In-Part US20070173474A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,804 Continuation-In-Part US20070173475A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,817 Continuation-In-Part US20070167390A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,773 Continuation-In-Part US20070123484A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,799 Continuation-In-Part US20070179106A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,823 Continuation-In-Part US20070179108A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,839 Continuation-In-Part US20070179109A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,785 Continuation-In-Part US20070185047A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,781 Continuation-In-Part US20070185046A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,833 Continuation-In-Part US20070172948A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,841 Continuation-In-Part US20070167391A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,816 Continuation-In-Part US20070179107A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,858 Continuation-In-Part US20070167392A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation
US11/565,770 Continuation-In-Part US20070166734A1 (en) 2004-06-03 2006-12-01 Double strand compositions comprising differentially modified strands for use in gene modulation

Publications (1)

Publication Number Publication Date
WO2005121368A1 true WO2005121368A1 (fr) 2005-12-22

Family

ID=35503075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017522 WO2005121368A1 (fr) 1996-06-06 2004-06-03 Compositions chimeriques oligomeres a breche

Country Status (6)

Country Link
US (1) US20080261904A1 (fr)
EP (1) EP1766052A4 (fr)
JP (1) JP2008501335A (fr)
AU (1) AU2004320622B2 (fr)
CA (1) CA2569036A1 (fr)
WO (1) WO2005121368A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766071A2 (fr) * 2004-06-03 2007-03-28 Isis Pharmaceuticals, Inc. Composition a double brin comprenant des brins différentiellement modifiés utilisés dans la modulation génétique
EP2182063A2 (fr) * 2003-09-18 2010-05-05 Isis Pharmaceuticals, Inc. Modulation de l'expression EIF4E
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US9096851B2 (en) 2008-08-25 2015-08-04 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2015106128A3 (fr) * 2014-01-09 2015-10-08 Alnylam Pharmaceuticals, Inc. Agents d'arni modifiés
US9765338B2 (en) 2010-07-19 2017-09-19 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (DMPK) expression
US10138482B2 (en) 2015-04-16 2018-11-27 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
US10954519B2 (en) 2013-08-09 2021-03-23 lonis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
JP6508716B2 (ja) * 2015-05-01 2019-05-08 学校法人北里研究所 膀胱癌細胞のシスプラチン耐性マーカー及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5023243A (en) * 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JPS5927900A (ja) * 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4824941A (en) * 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) * 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4828979A (en) * 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US5405938A (en) * 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5317098A (en) * 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
DE3788914T2 (de) * 1986-09-08 1994-08-25 Ajinomoto Kk Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
DE3738460A1 (de) * 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
JP3019994B2 (ja) * 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5082830A (en) * 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
WO1989009221A1 (fr) * 1988-03-25 1989-10-05 University Of Virginia Alumni Patents Foundation N-alkylphosphoramidates oligonucleotides
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) * 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5194599A (en) * 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5512439A (en) * 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5591722A (en) * 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) * 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5292873A (en) * 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) * 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5486603A (en) * 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5587470A (en) * 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5623065A (en) * 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
WO1991013080A1 (fr) * 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides, pseudonucleotides et leurs polymeres
US5214136A (en) * 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
EP0455905B1 (fr) * 1990-05-11 1998-06-17 Microprobe Corporation Bâtonnets d'immersion pour l'essai d'hybridition des acides nucléiques et procédés pour l'immobilisation covalente d'oligonucléotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) * 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5386023A (en) * 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) * 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
CA2088258C (fr) * 1990-07-27 2004-09-14 Phillip Dan Cook Oligonucleotides modifies par la pyrimidine resistants a la nuclease, detectant et modulant l'expression genique
US5177196A (en) * 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) * 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) * 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
JPH06505704A (ja) * 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
CA2095212A1 (fr) * 1990-11-08 1992-05-09 Sudhir Agrawal Incorporation de multiples groupes de ligands sur des oligonucleotides synthetiques
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
ES2103918T3 (es) * 1991-10-17 1997-10-01 Ciba Geigy Ag Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5595726A (en) * 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
EP0577558A2 (fr) * 1992-07-01 1994-01-05 Ciba-Geigy Ag Nucléosides carbocycliques contenant des noyaux bicycliques, oligonucléotides en dérivant, procédé pour leur préparation, leur application et des intermédiaires
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
GB9304620D0 (en) * 1993-03-06 1993-04-21 Ciba Geigy Ag Compounds
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5614621A (en) * 1993-07-29 1997-03-25 Isis Pharmaceuticals, Inc. Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
US5502177A (en) * 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) * 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5597696A (en) * 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) * 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) * 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) * 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
DE59607750D1 (de) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5705621A (en) * 1995-11-17 1998-01-06 Isis Pharmaceuticals, Inc. Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
WO2005121371A2 (fr) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Composition a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
ATE232880T1 (de) * 1996-11-18 2003-03-15 Takeshi Imanishi Neue nucleotidanaloga
US6172209B1 (en) * 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
WO1999001579A1 (fr) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions et procedes d'apport d'oligonucleotides par le tube digestif
US6028183A (en) * 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
US6020475A (en) * 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
US6169177B1 (en) * 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
WO2000050050A1 (fr) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Formulation multiparticulaire
US6033910A (en) * 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
ATE350473T2 (de) * 2002-08-05 2007-01-15 Atugen Ag Weitere neue formen von interferierende rns moleküle
EP1560839A4 (fr) * 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Composes oligomere chimeres et leur utilisation dans la modulation genique
EP2957568B1 (fr) * 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprenant en alternance des nucléosides 2'-modifiées destinées à être utilisées dans la modulation génique
AU2004274021B2 (en) * 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6107094A (en) * 1996-06-06 2000-08-22 Isis Pharmaceuticals, Inc. Oligoribonucleotides and ribonucleases for cleaving RNA

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRANCH A.D. ET AL: "A good antisense molecule is hard to find", TIBS, vol. 23, 1998, pages 45 - 50, XP004108000 *
BRANTL S. ET AL: "Antisense-RNA regulation and RNA interference", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1575, 2002, pages 15 - 25, XP004356720 *
CHIU ET AL: "siRNA function in RNAi: A chemical modification analysis", RNA, vol. 9, 2003, pages 1034 - 1048, XP002336178 *
ELBASHIR ET AL: "Functional Anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBOY JOURNAL, vol. 20, 2001, pages 6877 - 6888, XP002225998 *
JEN ET AL: "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies", STEM CELLS, vol. 18, 2000, pages 307 - 319 *
PARRISH ET AL: "Functional Anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interface", MOLECULAR CELL, vol. 6, 2000, pages 1077 - 1087, XP002226298 *
See also references of EP1766052A4 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182063A2 (fr) * 2003-09-18 2010-05-05 Isis Pharmaceuticals, Inc. Modulation de l'expression EIF4E
EP2256200A3 (fr) * 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation de l'expression de eIF4E
EP2182063A3 (fr) * 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation de l'expression EIF4E
US8410074B2 (en) 2003-09-18 2013-04-02 Isis Pharmaceuticals, Inc. Modulation of eIF4E expression
EP1766071A4 (fr) * 2004-06-03 2009-11-11 Isis Pharmaceuticals Inc Composition a double brin comprenant des brins différentiellement modifiés utilisés dans la modulation génétique
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP1766071A2 (fr) * 2004-06-03 2007-03-28 Isis Pharmaceuticals, Inc. Composition a double brin comprenant des brins différentiellement modifiés utilisés dans la modulation génétique
US9688987B2 (en) 2008-08-25 2017-06-27 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US9096851B2 (en) 2008-08-25 2015-08-04 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US9765338B2 (en) 2010-07-19 2017-09-19 Ionis Pharmaceuticals, Inc. Modulation of dystrophia myotonica-protein kinase (DMPK) expression
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US10577604B2 (en) 2012-10-15 2020-03-03 Ionis Pharmaceuticals, Inc. Methods for monitoring C9ORF72 expression
US10954519B2 (en) 2013-08-09 2021-03-23 lonis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US11339393B2 (en) 2013-10-11 2022-05-24 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2015106128A3 (fr) * 2014-01-09 2015-10-08 Alnylam Pharmaceuticals, Inc. Agents d'arni modifiés
US10119136B2 (en) 2014-01-09 2018-11-06 Alnylam Pharmaceuticals, Inc. RNAi agents modified at the 4′-C position
US10138482B2 (en) 2015-04-16 2018-11-27 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression

Also Published As

Publication number Publication date
AU2004320622B2 (en) 2012-06-14
AU2004320622A1 (en) 2005-12-22
EP1766052A1 (fr) 2007-03-28
EP1766052A4 (fr) 2009-12-16
CA2569036A1 (fr) 2005-12-22
JP2008501335A (ja) 2008-01-24
US20080261904A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
EP1765074B1 (fr) PRODUITS DE SYNTHESE D'ARNsi MODIFIES EN POSITION
EP1560840B1 (fr) Compositions comprenant des nucleosides modifies en 2' de substitution destinees a la modulation de gene
US8569474B2 (en) Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2004044140A2 (fr) Composes oligomeres 2'-substitues et compositions destinees a etre utilisees dans des modulations genetiques
WO2005044976A2 (fr) Composes oligomeres utilises pour la modulation de genes
EP1644475A2 (fr) Compositions bicatenaires comprenant une chaine 3'-endo modifiee destinees a etre utilisees en modulation genique
AU2004320622B2 (en) Chimeric gapped oligomeric compositions
CA2504720C (fr) Composes oligomere chimeres et leur utilisation dans la modulation genique
WO2004041924A2 (fr) Composes oligomeres a liaison non phosphore et leur utilisation pour la modulation genique
WO2004044134A2 (fr) Composes oligomeriques lies par phosphore et utilisation dans la modulation de gene
EP1578761A2 (fr) Motifs structurels, composes oligomeriques et utilisation de ceux-ci dans la modulation de gene
WO2004044137A2 (fr) Composes et compositions oligomeriques contenant un substitut de sucre et de squelette destines a la modulation de gene
WO2006034321A2 (fr) Composes oligomeres effectuant un clivage dans lequel drosha joue un role d'intermediaire
AU2011203091B2 (en) Chimeric oligomeric compounds and their use in gene modulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004320622

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11565781

Country of ref document: US

Ref document number: 11565785

Country of ref document: US

Ref document number: 11565799

Country of ref document: US

Ref document number: 11565816

Country of ref document: US

Ref document number: 11565823

Country of ref document: US

Ref document number: 11565839

Country of ref document: US

Ref document number: 11565773

Country of ref document: US

Ref document number: 11565794

Country of ref document: US

Ref document number: 11565770

Country of ref document: US

Ref document number: 11565858

Country of ref document: US

Ref document number: 11565817

Country of ref document: US

Ref document number: 11565833

Country of ref document: US

Ref document number: 11565841

Country of ref document: US

Ref document number: 11565804

Country of ref document: US

Ref document number: 2569036

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007515019

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004754188

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004320622

Country of ref document: AU

Date of ref document: 20040603

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004754188

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11565773

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11565817

Country of ref document: US

Ref document number: 11565770

Country of ref document: US

Ref document number: 11565841

Country of ref document: US

Ref document number: 11565858

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11565804

Country of ref document: US

Ref document number: 11565794

Country of ref document: US

Ref document number: 11565833

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11565839

Country of ref document: US

Ref document number: 11565823

Country of ref document: US

Ref document number: 11565799

Country of ref document: US

Ref document number: 11565816

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 11565785

Country of ref document: US

Ref document number: 11565781

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 11569941

Country of ref document: US